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Abstract 
Hepatocellular carcinoma is the sixth most common malignancy worldwide and the third 
most common cause of death from cancer. In Australia, 1,778 patients were diagnosed 
with a primary liver cancer in 2013 with an age-standardised rate of 6.9/100,000 people. 
For a selected group of patients, liver transplantation represents the best chance of cure. 
Transplantation not only removes the disease, it also removes the abnormal liver 
parenchyma that provides a fertile ground for development and growth of new disease. 
Appropriate patient selection forms the cornerstone for any transplantation service, and 
organ shortages necessitate an efficient allocation of resources and careful prioritisation of 
the transplantation waiting list in order maximise benefit over a large patient cohort. 
Current allocation schemes are primarily based on tumour morphology. The goal of this 
thesis is to analyse pre-transplant radiological and biochemical markers in order to identify 
markers of poor prognosis that may be used to modify selection criteria. 
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Introduction 
Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the 
third most common cause of death from cancer (2). In Australia, 1,778 patients were 
diagnosed with a primary liver cancer in 2013 with an age-standardised rate of 
6.9/100,000 people (3). For a selected group of patients, liver transplantation (LT) 
represents the best chance of cure. Transplantation not only removes the disease, it also 
removes the abnormal liver parenchyma that provides a fertile ground for development of 
and growth of new disease. Appropriate patient selection forms the cornerstone for any 
transplantation service, and organ shortages necessitate an efficient allocation of 
resources and careful prioritisation of the transplantation waiting list in order maximise 
benefit over a large patient cohort. Current allocation schemes are primarily based on 
tumour morphology.  
The goal of this thesis is to analyse pre-transplant radiological and biochemical markers in 
order to identify markers of poor prognosis that may be used to modify selection criteria. 
This introduction will briefly discuss epidemiology and current treatments available for 
HCC. Each subsequent chapter then represents a self-contained publication or manuscript 
submitted for publication at the time of thesis submission. 
Epidemiology and Risk Factors for Hepatocellular Carcinoma 
Hepatocellular carcinoma is the most common form of primary liver cancer (4). In Australia, 
the most common primary aetiology for the development of HCC is chronic hepatitis C 
virus (HCV), followed by chronic hepatitis B virus (HBV) (5). This distribution is reversed in 
geographies with a high prevalence of HBV (e.g. West Africa, China), where it supplants 
HCV as the primary aetiology (4). In the vast majority of cases it develops in a cirrhotic 
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liver, with the incidence of HCC in such livers estimated at 3-5% per year (6). Other risk 
factors include alcoholic cirrhosis, non-alcoholic fatty liver disease/non-alcoholic 
steatohepatitis (NAFLD/NASH),  and immunological diseases such as primary biliary 
cirrhosis (PBC) (2). Obesity and diabetes have also been shown to be significant risk 
factors, with one study in the United States concluding that eliminating obesity and 
diabetes could have a greater effect on reducing the incidence of HCC than the elimination 
of any other single risk factor (7). The ratio of gender-specific incident rate worldwide is 
approximately 2.4 towards males (8). This ratio increases in higher-prevalence areas. At 
the Australian National Liver Transplantation Unit (ANLTU), HCV was the most common 
primary disease associated with HCC in patients who underwent liver transplantation 
between 2012 and 2016 (9). This was an increase from 30% from the 1986-1996 period. 
Notably, the NAFLD/NASH cohort went from 0% to 10% over the same period.  
Historically, survival of patients with HCC has been grim. In 1984, Okuda et al. published a 
median survival of 1.6 months in patients who did not receive any treatment, compared to 
a median survival of 19.6 months in patients who underwent surgical resection (SR) (10). In 
contemporary literature, patients who undergo liver transplantation can expect 5-year 
survival in excess of 60%, with equivalent survival in patients with small tumour burden 
who are eligible for surgical resection (11). 
Staging 
There are multiple staging techniques available for HCC, however the Barcelona Clinic 
Liver Cancer (BCLC) classification is the most widely used (Table 1)(12, 13). It consists of 
Child-Pugh classification, ECOG performance status and tumour morphology. The 
classification has been validated and accepted by both European Association for the 
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Study of the Liver (EASL) and the American Association for the Study of Liver Disease 
(AASLD) and is the de facto staging system used in clinical trials. It is the only staging 
system to incorporates both staging and recommended treatment with a standard of care 
for every stage (Figure 1). 
Table 1 - BCLC Classification 
 BCLC Stage 
 Very early stage 
(0) 
Early stage (A) Intermediate 
stage (B) 
Advanced stage 
(C) 
Terminal stage 
(D) 
Child-Pugh 
classification 
A A-B A-B A-B C 
Performance 
status 
0 0 0 1-2 3-4 
Tumour status 1 HCC < 2cm 
Carcinoma in 
situ 
1 HCC or 3 
nodules < 3cm 
Multinodular Portal invasion 
or N1/M1 
Terminal stage 
Other staging systems include the Chinese University Prognostic Index (CUPI) and the 
Japan Integrated Staging (JIS), which now includes biomarker information (14, 15). 
Figure 1 BCLC Staging system and treatment strategy. Adapted from (1). 
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Treatment 
Treatment for HCC includes surgical options, locoregional therapies (LRT) such as 
transarterial chemoembolisation (TACE), and systemic therapies such as sorafenib. Liver 
transplantation is considered the optimal therapeutic option in appropriately selected 
patients (16). However, organs are a scarce resource and advanced stage cancers are not 
suitable for LT, leading to many patients being without this option. Choice of therapy for an 
individual patient relies on many facets of the disease, such as severity of underlying liver 
disease (e.g. Child-Pugh score, degree of portal hypertension), morphology and 
anatomical location of the tumour(s), and local guidelines for transplantation listing and 
prioritisation. 
Locoregional therapies 
Locoregional therapies for the treatment of HCC include TACE and percutaneous ablations 
such as percutaneous ethanol injection (PEI) and radiofrequency or microwave ablation 
(RFA, MWA). They are generally considered non-curative options, but have the potential to 
be curative in selected patients such as those with single tumours < 2cm (17). These 
therapies can be used on their own or in combination in patients not suitable for 
transplantation or resection (18, 19).  In the context of LT, LRTs have been used as either a 
bridging strategy, to maintain a patient on a transplant waiting list, or a downstaging 
strategy, to make a patient eligible for transplant.  
Percutaneous ablation 
Percutaneous ablation is considered the best modality for patients who are not candidates 
for SR or LT. Of the available options, RFA has been shown to be superior in terms of 
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complete response rates to PEI on meta-analysis (20, 21). It also required fewer treatment 
sessions and shorter hospitalisation, with no significant difference in major complications. 
Thus, RFA is recommended over PEI unless it is not possible due to resource limitations or 
tumour location (e.g. pericholecystic). Ablative therapies can achieve complete response in 
over 80% of tumours smaller than 3cm, with this rate dropping at the tumour size 
increases. Five-year survival rates have been demonstrated to be between 40 and 70% 
(22). 
Transarterial chemoembolisation 
Transarterial chemoembolisation (TACE) involves the transcatheter delivery of a cytotoxic 
agent followed by the embolisation of the arterial tumour feeding vessels. HCCs 
increasingly rely on arterial over portal venous supply as they enlarge, hence the rational of 
combining a cytotoxic effect with that of ischaemia (22). Conventional TACE generally uses 
cisplatin or doxorubicin as the cytotoxic agent. More recently TACE with drug-eluting 
beads (TACE-DEB) has been developed which releases the cytotoxic agent over a one-
week period, and has shown to significantly reduce liver toxicity and systemic side effects 
(23). There is conflicting evidence over the efficacy of TACE, with the most recent 
Cochrane review unable to support or refute the use of TACE or Transarterial embolization 
(TAE) (24). Previous meta-analysis had demonstrated survival benefit over 2 years (41% vs 
27%, p=0.017), however, and on balance of existing evidence TACE has become 
accepted as the first line treatment for patients with intermediate, unresectable disease 
without vascular invasion or extrahepatic spread (1, 25, 26). Furthermore, there is evidence 
that combination of TACE with ablative techniques provides a survival benefit over TACE 
alone (27). 
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Locoregional therapies and liver transplantation 
As previously mentioned, LRT can be used in association with LT for the purpose of 
bridging, maintenance or downstaging. Maintenance refers to stabilising tumour load so 
that a patient does not drop-off the waiting list; downstaging is bringing a patient from 
outside selection criteria to within it. Current guidelines from EASL and AASLD both 
suggest treatment of patients on the waiting list for LT with LRT if the expected waiting 
time is greater than 6 months, however due to uncertainty in waiting times the majority of 
patients will undergo some variation of LRT (1, 26). In a recent meta-analysis of current 
evidence for pre-transplant LRT, the authors conclude that there are non-statistically 
significant trends in reduced waitlist drop-off and improved post-transplant outcomes in 
patients treated with LRT, however no RCTs were identified and the available comparative 
studies had a high risk of selection bias (28). As further discussed in Chapter 1, there is 
increasing interest in the predictive value of response to pre-transplant treatments on 
post-transplant survival and recurrence. 
Surgical resection 
Surgical resection (SR) is the treatment of choice in patients with single tumours and well-
preserved liver function (1). According to the AASLD, surgical resection can also be 
considered in patients with the following characteristics (26): 
1. 1-3 unilobar lesions; 
2. an upper size limit of 5 cm for single lesions and 3 cm for more than 1 lesion; 
3. no radiographic evidence of macrovascular invasion or extrahepatic disease; 
4. minimal or no portal hypertension; 
5. no synthetic dysfunction. 
 15 
Portal hypertension has been validated as a prognostic indicator, and can be measured 
clinically by splenomegaly, the presence of oesophageal varices, and a platelet count of 
less than 100,000/mm3 (29). Anatomical resections following Couinaud segments have 
been demonstrated to achieve a better recurrence-free survival, as do surgical resection 
margins of 2cm vs 1cm (30, 31); however, surgical margin must be balanced against the 
need to maintain a safe future liver remnant. Randomised controlled trials have shown SR 
to be superior to ablative therapies in terms of overall survival (OS) (32, 33). Currently, the 
AASLD recommends SR over ablation in patients with early stage (T1-T2) disease and 
minimal or no synthetic dysfunction, with a similar recommendation from EASL (1, 26). SR 
may not be possible in patients with bilobar disease, and unlike LT the remnant liver still 
maintains malignant potential (34). OS is approximately 60% at 5 years, however 
recurrence rates are high (70% at 5 years); these rates are worsened by factors such as 
vascular invasion, tumour size and multi-focality (29, 35). 
The choice between SR and LT in patients with small tumour burden and well-preserved 
hepatic function continues to evolve. It depends on local transplantation guidelines, 
availability of organs and surgical expertise. It has been established that LT leads to 
improved 5-year RFS after surgery compared to SR (11, 16, 34). However, when 
performing intention-to-treat analysis and including the effect of waiting list drop-off in the 
analysis the definitive answer is less obvious. In a recent meta-analysis, Menahem et al. 
concluded that, for patients within MC, LT had a significantly increased OS over SR at 10 
years, however it had a significantly improved disease-free survival at only 3 years (36). 
Various groups worldwide have suggested that resection followed by salvage 
transplantation is a valid approach, as the initial resection allows gathering of tumour 
histopathology. 
 16 
Liver transplantation 
The first successful liver transplant was performed in 1967 by American surgeon Thomas 
Starzl (37). In Starzl’s report of his initial series overall 1-year survival was approximately 
20% (38). For several decades LT for HCC resulted in poor post-transplant survival and 
high recurrence rates, results which were attributed to difficulty in selecting appropriate 
patients (5-year overall survival of 16-36%) (39, 40). To complicate matters further, any 
selection criteria must also take into account the impact it will have on patients on the 
waiting list for other liver diseases. It was not until 1996, when Mazzaferro et al. reported 
an improved 4-year overall survival (OS) of 85% in highly selected patients (Table 2), that 
transplantation for HCC had its first widely accepted selection criteria. These have become 
known as the Milan Criteria (MC), and are considered the benchmark to which other 
selection criteria must be measured (41). Since the introduction of MC, centres worldwide 
have investigated ways of expanding these criteria whilst still ensuring acceptable survival 
and recurrence rates. The University of California, San Francisco (UCSF) criteria showed 5-
year OS of 64% compared to 79% for MC in their cohort (p=0.061) (42). The original 
authors of MC subsequently published the “Up-to-Seven” criteria in 2009, demonstrating a 
5-year OS of 71.2% (43). 
Table 2 – Morphological selection criteria for liver transplantation 
MC UCSF Up-to-seven 
Single tumour ≤ 5cm, 
or 
≤ 3 tumours, all ≤ 3cm 
each 
Single tumour ≤ 6.5cm, 
or 
≤ 3 tumours, all ≤ 4.5cm, 
cumulative size < 8cm 
Sum of the size of the 
largest tumour in cm and 
the total number of 
tumours ≤ 7 
* no microvascular invasion 
 
 17 
These selection criteria rely solely on a static reading of tumour morphology. In order to 
further refine selection criteria, there has been growing interest in recent years into 
dynamic markers that reflect tumour biology, and hence may aid in predicting patients 
who will benefit more from transplantation (and conversely, those that are at risk of poor 
survival post-transplantation) (44). Proxies acting for this biological criteria have been 
suggested by various groups, including alpha-fetoprotein (AFP) levels (45-48), neutrophil-
to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios (49, 50), and response to pre-
LT LRT (51, 52). The remainder of this thesis addresses this current area of investigation. 
Chapter 1 comprises of a systematic review analysing the predictive value of radiological 
response to pre-transplant LRT on post-transplantation survival. Chapter 2 encompasses 
an intention-to-treat retrospective analysis of patients with HCC who were listed for LT at 
the Australian National Liver Transplantation Unit (ANLTU) in Sydney, Australia. This 
chapter investigates the relationship between radiological response to LRT and AFP to 
transplantation survival. Appendix 1 contains a short discussion of unpublished data 
relating to inflammatory markers and predicting survival. Appendix 2 contains a 
manuscript written during the time of this thesis candidature however is unrelated to the 
principal topic. 
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Chapter 1: Can response to locoregional therapy help 
predict long-term survival after liver transplantation for 
hepatocellular carcinoma? A systematic review. 
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Abstract 
Background 
For a selected group of patients with hepatocellular carcinoma, liver transplantation 
represents the best chance of cure. Organ shortages necessitate an efficient 
allocation of resources and careful prioritisation on the transplantation waiting list. 
In this review we aim to collate and evaluate the published evidence for using 
response to locoregional therapies, measured by mRECIST, as a predictor of long-
term survival after liver transplantation. 
Objective 
To assess whether response to locoregional therapies before LT for HCC, as 
measured by the RECIST or mRECIST criteria, can help predict recurrence-free 
and/or long-term survival outcomes. 
Data sources 
We searched MEDLINE, EMBASE and the Cochrane database. 
Study eligibility criteria 
We included randomised controlled trials, cohort, case control and case series 
studies. Poster and conference abstracts were included. Studies were required to 
use RECIST or mRECIST criteria when assessing tumour response and were limited 
to LT for HCC only. 
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Search results 
15 records were included in the final systematic review, 7 published manuscripts 
and 8 conference abstracts.  
Limitations 
No randomised controlled trials were identified. Several included papers were 
conference abstracts with limited data available. 
Conclusions and key findings 
No randomised controlled trials were found and no meta-analysis was undertaken. 
Several retrospective cohort studies were identified which demonstrated statistically 
significant differences in survival and recurrence between different RECIST criteria 
after liver transplant. 
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Introduction 
For a selected group of patients with hepatocellular cancer (HCC), liver 
transplantation (LT) represents the best chance of cure. Transplantation not only 
removes the primary lesion, it also removes the diseased liver that provides a fertile 
ground for the development and growth of new disease. Appropriate patient 
selection forms the cornerstone for any transplantation service. Mazzaferro et al. 
reported acceptable survival results for patients with limited disease burden (a 
single HCC lesion <5cm in size or 3 or fewer lesions with the largest <3cm in size) – 
the Milan Criteria (MC) (1). Since then the parameters of acceptable outcomes for 
transplantation for HCC have been expanded upon by various groups (2).  
In the context of LT, locoregional therapies have been used as either a bridging 
strategy, to maintain a patient on a transplant waiting list, or a downstaging 
strategy, to make a patient eligible for transplant. Many different types of 
locoregional therapy exist, including transarterial chemoembolization (TACE), 
radiofrequency or microwave ablation (RFA/MWA) and percutaneous ethanol 
injections (PEI). These therapies can also be used on their own or in combination 
outside of the transplant setting in patients not suitable for transplantation or 
resection (3, 4). 
Organ shortages necessitate efficient allocation of resources and prioritisation of 
the waiting list. Treatment on the waiting list with LRT to avoid dropout is 
recommended based on current evidence (5); however, no such recommendation 
exists for using response to LRT as a predictor of post-transplant outcome (6). It is 
possible that response to treatment is such a strong predictor of recurrence after 
transplant and/or waiting list dropout that it should influence both eligibility criteria 
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for transplant and prioritisation for transplant (through for instance a modification of 
tumour MELD). In recent years, interest has been shown in the effect that 
locoregional therapies have on long-term survival post-transplantation, with the 
view to using this information in determining a “biological selection” criteria to 
appropriately expand the purely size based MC or UCSF criteria (7). However, 
definite recommendations remain elusive (8).  
There are multiple ways of measuring tumour response; this review will look at pre-
transplant radiologic response as measured by the Response Evaluation Criteria in 
Solid Tumours (RECIST) (9) or modified RECIST (mRECIST) (10). The RECIST 
criteria categorise tumour response into four categories: complete response (CR), 
partial response (PR), stable disease (SD) and progressive disease (PD), based on 
radiological investigations. The modified criteria were created specifically for HCCs 
to make assessing response to molecular-targeted therapies or locoregional 
therapies more consistent by introducing measurement of arterial phase 
enhancement. Other options for response measurement include changes in pre-
transplant alpha fetoprotein (AFP) levels (11-13) and explant tumour necrosis (14, 
15). 
Methods 
Eligibility criteria 
We limited our search to the years 1980–2016 English language only. Randomised 
controlled trials, cohort, case control and case series studies were included, 
including conference poster and verbal presentations. Only LT for HCC was 
considered. Locoregional therapies including TACE, RFA, PEI and surgical resection 
were considered; however, studies looking only at surgical resection before salvage 
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transplantation were excluded. Appropriate imaging before and after LRT was 
required, and the response must have been reported in terms of RECIST or 
mRECIST. At least 3-year recurrence-free or overall survival had to be reported to 
ensure adequate follow-up periods were used. 
Information sources 
Medline via OvidSP, Embase and the Cochrane databases were searched. Authors 
of conference abstracts in the final review were contacted if possible to provide 
additional data. 
Search 
A comprehensive search using the key terms liver transplantation; overall, 
recurrence-free and disease-free survival; TACE, RFA, PEI, cryotherapy, and yttrium 
radioisotopes and their synonyms, was undertaken on 8 June 2015. A simplified 
search of HCC treatment was performed on the Cochrane database. The search 
strategy was formulated by all authors. 
Study selection 
The search results from the two databases used were merged and duplicates 
removed automatically in Endnote. Studies were screened initially by title alone, 
followed by abstract, with duplicates that were missed by automatic matching 
removed manually. A full text review was performed on a short list of papers when 
available (i.e. not a poster presentation). A final decision on full papers to include in 
the qualitative analysis, and conference abstracts to request further data on, was 
made. One author (PM) screened studies by title and abstract. Two authors (PM 
and CS) performed the full text review. 
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Data collection process 
Data were manually extracted into Review Manager by PM and validated by CS. 
Data points to extract were agreed on by all authors. A standardised extraction form 
was used. A standard request for data form was sent to the authors of conference 
abstracts to provide further information not available in the abstract. If returned, this 
data was included in the review.  
Data items 
We extracted the following items from each paper where it was reported: 
• Paper characteristics: including study type, centre type, LT, TACE and 
analysis inclusion and exclusion criteria. 
• Population: including sample size, baseline characteristics (e.g. MELD scores, 
HCC aetiology), and follow-up period. 
• Interventions: types of LRT used and numbers associated with each therapy. 
• Outcomes: hazard ratios, 5-year recurrence-free survival, 5-year overall 
survival for each RECIST criteria where reported. Other important conclusions 
of the study were also recorded. 
Summary measures 
The principle summary measures are 5-year recurrence-free and overall survival. 
Synthesis of results 
Data were arranged in tabular form and qualitatively reviewed. No meta-analysis 
was undertaken owing to a lack of RCTs and heterogeneity between studies. 
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Hazard ratios were estimated using Peto’s method (16). This systematic review was 
performed according to the PRISMA guidelines (17). 
Results 
Study selection 
The search yielded a total of 4,441 papers from Medline and Embase. No relevant 
entries were found in the Cochrane database. No papers from other sources were 
included. 911 duplicates were identified either automatically by Endnote or manually 
by the authors. The remaining 3,530 papers were screened initially by title, leaving 
383 papers, then by abstract, leaving 65 possible papers for full text review. Of 
these papers, 18 were included in an initial short list; however, 3 conference 
abstracts were removed after authors did not respond to requests for further data. 
15 studies were included in the final selection – 1 published prospective cohort 
study (18), 6 published retrospective cohort studies (19-24) and 8 conference 
abstracts (25-32). We had access to additional data and an unpublished manuscript 
for 1 conference abstract (25). The selection process is shown in Figure 1. 
Study characteristics 
Study characteristics and their patient populations are displayed in Table 1a and 1b 
(published manuscripts and conference abstracts, respectively). One prospective 
and one multicentre study were found, (18) and (21), respectively. These papers 
represent cohort analyses of a total of 1885 patients who received both LRT and a 
liver transplant.  Age and sex distribution of the populations was similar for all 
studies (mean/median age 56.94-65, percentage male 72.8-85.3% where reported). 
All papers included multiple aetiologies for HCC except Sogawa et al. (27), which 
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included only HCV patients. Maximum study duration was 19 years (20). Follow-up 
periods ranged from a median of 24.3 months (19) to 6.5 years (20). Two studies 
were reported as intention-to-treat for all patients listed for LT (18, 19). Only 1 
published manuscript explicitly stated the inclusion of living-donor liver transplants 
in their cohort (24). Two published manuscripts had study periods that were entirely 
within the MELD era (19, 23), others spanned pre- and post-MELD. Differences 
were noted in the inclusion and exclusion criteria for the study, LRT and listing for 
LT. For example, the inclusion criteria for pre-LT TACE for Otto et al. was age < 71, 
cirrhosis, ≥ 2 cycles of TACE, HCC < 10cm irrespective of number of lesions and 
absence of factors contraindicating OLT; in comparison, Shuster et al. used any 
single tumour > 5 cm in maximal diameter, three or more nodules > 3 cm, Child-
Pugh class A and B, normal left ventricular ejection fraction (55%–80%), and 
Eastern Cooperative Oncology Group performance status 0–1 (22, 23). 
Sample sizes of patients who received both LT and LRT range from 20 to 422. 
Locoregional therapies also varied, with TACE as the most common treatment 
overall. 8 studies used only TACE; all studies that included multiple interventions 
had TACE as one of those. The reported patient and tumour characteristics, for 
example tumour stage or number/size, were also variable.  
Results of individual studies 
Numerical results of each study are given in Table 2a and 2b for published 
manuscripts and conference abstracts, respectively. Locoregional therapies 
included TACE, RFA, PEI, LR, radiotherapy and various combinations of these.  
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Overall Survival and Recurrence 
Several papers reported a statistically significant improvement in both RFS and OS 
at 5 years. Lai et al. (21) presents the largest patient cohort and analyses both AFP 
changes and mRECIST and. This paper showed that PD was associated with HR 
3.5 (p<0.001) and 1.6 (p<0.04) compared to CR, PR or SD for RFS and OS, 
respectively. Sandroussi et al. (25) showed survival rates stratified by criteria (CR = 
84%/84%, PD = 41%/52%, p=0.003/0.04, RFS and OS respectively). Jiangyong et 
al. (32) showed an improvement in the group with a CR or PR compared with SD or 
PD (75% vs. 54.9%, p=0.02 for OS, RFS data not available, abstract only). 
Additionally, Lai et al. have shown that AFP can be used as a pre-transplant marker 
for biological selection by demonstrating that a gradient of >15ng/mL/month is 
significantly associated with reduced RFS and OS (HR 5.4 and 3.8, respectively, 
p<0.001). Sandroussi et al. also showed that response as measured by RECIST was 
the only pre-transplant variable that predicted RFS when compared to AFP > 
400ng/mL, MELD, tumour size and number, aetiology, and grade at transplant 
(unpublished data). 
Two published manuscripts demonstrated an improvement in 5-year OS but not 
RFS. Millonig et al. (18) and Shuster et al. (23) both report that patients who had CR 
or PR had significantly longer OS compared to SD or PD (CR = 85.1% vs. SD+PD = 
51.4%, p=0.02; CR+PR = 89.9% vs. SD+PD = 34.3%, p=0.02, respectively). Millonig et al. also 
do an intention-to-treat (ITT) analysis on all patients listed for transplant who 
received LRT. This shows a greater statistical impact on 5-year OS of 85.7% for CR 
compared to 19.3% for SD or PD (p<0.01). Despite these results, they conclude 
that tumour stage and waiting time are the most important factors influencing 
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outcome after LT. Additionally, Shuster et al. showed that response measured 
according to the RECIST criteria was superior to the EASL criteria at predicting 
long-term post-transplant survival (p=0.005). 
Several authors (19, 20, 22, 24, 26, 30, 31) reported recurrence free survival data 
only. Both Cucchetti et al. (19) and De Simone et al. (26) have found that the group 
with CR had a significant decrease in the recurrence risk compared to SD, PR or 
PD, but no effect on survival (recurrence rate 5.5 vs. 19.4% p=0.02; RFS 100 vs. 
86.8%, p=0.006, respectively). Both these cohorts included patients initially 
satisfying MC. Cucchetti et al. also did an intention-to-treat analysis and showed 
that 5-year OS was significantly impacted by response criteria - patients with CR 
having a survival of 66.4% compared to PR, SD or PD with 45% (p=0.001). This 
statistical significance was not found when analysing only the LT cohort (p=0.10). 
Furthermore, they demonstrated that CR reduced the probability of drop-off after 12 
months on the waiting list compared to other RECIST criteria (9.4% vs. 28.9%, 
p<0.001). Seehofer et al. (20) found that PD was significantly associated with an 
increased recurrence rate, but only for patients outside of MC at listing (p=0.047). 
On multivariate analysis of all patients in their study (i.e. patients who received 
TACE and those who did not), they found that changes according to the RECIST 
criteria were associated with a significant increase in recurrence rate (HR 2.12, 
p=0.02), but not associated with overall survival (HR 1.04, p=0.88). Furthermore, 
Seehofer et al. found no statistically significant impact on waiting time to LT, 
recurrence or survival between those who received TACE and those that did not. 
Otto et al. (22) have shown that there was a significant reduction in recurrence free 
survival for the PD group compared to SD or PR (RFS 22 vs. 88%, p<0.001, 
respectively). This paper also defines an “any progression” category - any increase 
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in size and/or the appearance of new measurable lesions - which was associated 
with a more pronounced difference between those inside AP than those outside (21 
vs. 92%, p<0.001, respectively). Kim et al. (24) demonstrated that both 5-year RFS 
and recurrence rate were significantly better for patients with a CR or PR compared 
to SD or PD (recurrence rate 5.3 vs. 17.6%, p=0.01, respectively). Nicolini et al. (31) 
and Na et al. (30) both described SD or PD as independent risk factors of 
recurrence (p=0.03 and p=0.04, respectively, both conference abstracts).  
In contrast to the other groups, Sogawa et al. (27), Mannina et al. (28) and Han et al. 
(29) did not identify a significant effect on OS or RFS in terms of response to 
locoregional treatment as measured by RECIST (all 3 conference abstracts).  
Milan criteria 
Several papers made observations about the use of RECIST and the Milan criteria 
(18, 20-22, 25). Millonig et al. (18) demonstrated that those within MC (MC-IN) who 
had SD or PD on the waiting list had significantly worse OS compared to CR (1y OS 
37.5 vs. 89.2%, p=0.04). However, this did not apply to disease that extended 
beyond the MC (MC-OUT) (p=0.39 for UCSF). MC-IN patients were also less likely 
to be removed from the waiting list due to progression compared to UCSF, however 
not statistically significantly so (p=0.08). Sandroussi et al. (25) have shown similar 
results, concluding that MC-IN patients with CR, PR or SD had significantly 
improved RFS over PD (91 vs. 47%, p<0.001, respectively). There was no 
significant difference for MC-OUT patients. Lai et al. (21) have shown that patients 
who are initially MC-OUT but do not have PD or AFP slope > 15ng/mL/month after 
LRT can achieve a very good post-LT recurrence-free survival of 87%, significantly 
better than MC-IN patients who had one or both of the above (p=0.01). 
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Furthermore, they conclude that initially MC-OUT patients with a poor response 
after LRT should have their position on the transplant waiting list re-evaluated as 
they have significantly worse post-transplant survival (HR=3, p=0.02). MC-IN 
patients experiencing progression after LRT have an increased risk of tumour 
recurrence and death after LT in comparison with patients who have a complete 
response (recurrence/death HR=2.2/2 vs. 0.6/0.5, p=0.02/0.02).  Otto et al. (22) 
have shown that for patients who were MC-IN after TACE there was a significantly 
increased 5-year RFS compared to those patients who were MC-OUT after TACE 
patients (88 vs. 55%, p<0.001). However, there was no significant difference for 
MC-IN or MC-OUT at time of listing (81 vs. 77%, p=0.58), indicating that the tumour 
biology as predicted by the response to TACE had a significant effect on post-
transplant survival. Moreover, progressive disease was a stronger predictor of 5-
year recurrence than MC after TACE. In contrast, Seehofer et al. (20) showed that 
MC-OUT patients with PD had a significantly impacted risk of recurrence compared 
to CR, PR or SD (HR 3.2, p=0.01), a split that lost significance for MC-IN patients 
(HR 1.34, p=0.53). 
Discussion 
Summary of evidence 
This systematic review shows that there are demonstrable differences in survival 
when patients are stratified by (m)RECIST criteria; however, data presented are 
heterogeneous. Patient selection criteria varied between each study, as did 
therapeutic regimes, ranging from TACE only to multiple treatment modalities. 
Inclusion criteria to the study, LRT and listing for LT also varied between each 
study, and this is likely a significant contributor to heterogeneity. The effect that 
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tumour response had on long-term overall and disease-free survival varied, 
especially when comparing which differential of RECIST categories led to 
statistically significant results. Several papers reviewed were conference abstracts, 
limiting the applicability of the published statistics owing to limitations on the 
information provided about patient selection, tumour characteristics, treatment 
protocol and outcome data. 
Despite many of the selected papers identifying a significant improvement in both 
recurrence-free and overall survival for those who have a response to locoregional 
treatment, firm conclusions are difficult to draw. There is heterogeneity between 
RECIST criteria stratification and what significantly predicts survival. For example, 
out of the 5 published manuscripts that reported RFS only, 1 found CR improved it 
compared to the other categories and 3 found that PD reduced it. We demonstrate 
the published manuscripts that showed PD increased the risk of recurrence post-
transplant with a Forest plot of hazard ratios, without meta-analysis, in Figure 2. 
When reviewing published manuscripts that used only TACE (18, 20, 22-24), 3 out 
of 5 of these found statistically significant results when comparing CR or PR to SD 
or PD for either overall or recurrence-free survival, again showing heterogeneity in 
results even with the same LRT. 
Important observations about long-term outcomes when combining RECIST with 
the Milan criteria have also been made; however, as with recurrence and survival 
the data is heterogeneous. These results have identified the importance of tumour 
biology as a selection criterion for LT and in future the response to LRT according 
to the RECIST criteria may be used as a surrogate biological selection marker and 
hence inform decisions about patient suitability for LT. It is clear from many of the 
 36 
included studies that improvements can be made upon Milan (and by extension, 
UCSF) criteria, with multiple papers concluding that RECIST predicted long-term 
outcomes better than criteria at the time of listing or that combinations of the 
criteria and progression may help exclude patients who have a high likelihood of a 
poor post-transplant outcome. If modifications to criteria are to be considered, 
further controlled studies that can be repeated in different geographical regions are 
required that also consider the outcome of patients not enrolled on a LT waiting list 
at all. 
Other pre-transplant factors are also under investigation to determine if they can be 
used as reliable markers for tumour biology, including AFP level and gradient (33, 
34), and neutrophil-to-lymphocyte ratio (35, 36). 
Limitations 
The main limitation of this systematic review is that no RCTs were found; we 
identified only cohort studies. Many of these studies were conference abstracts 
only. No meta-analysis could be performed. There was much heterogeneity 
between published data in terms of locoregional therapy regimens, selection criteria 
to LRT and LT, and sub-group analysis to reach statistical significance. Ideally only 
mRECIST would have been an inclusion criterion; however, this would have resulted 
in many papers with important results being excluded. Only two studies included 
intention-to-treat analyses for all patients who received LRT when listed for 
transplantation, making conclusions about the overall impact response to therapy 
has difficult to draw. Many studies had progression on the waiting list as a criterion 
for exclusion from LT. This means any benefit seen from transplanting only patients 
with response to treatment is likely to be much greater on an intention basis than 
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has been demonstrated by these articles, as it was in the studies that performed an 
intention-to-treat analysis. 
Conclusions 
Appropriate allocation of finite deceased donor organs is fundamental to 
transplantation programs. Current allocation policies using only tumour size and 
number may be excluding patients outside these criteria who have biologically 
favourable disease and would achieve equivalent survival outcomes to those within 
such criteria. This systematic review seeks to look at one possible pre-transplant 
measurement of tumour biology – radiological response as measured by RECIST or 
mRECIST. All the data on this topic are derived from uncontrolled or non-
randomised comparative studies and heterogeneity was noted between patient 
selection, treatment and results. More prospective trials are clearly required. Also 
beneficial to the future study of this topic would be increased standardisation for 
locoregional therapies and consistent use of mRECIST rather than RECIST. This 
may lead to meta-analysis being possible even without RCTs. Based on current 
evidence, no definitive conclusions can be drawn. However, several papers did 
identify statistically significant results and we believe this topic is worthy of further 
investigation. In the future patients with complete response or progressive disease 
may be re-evaluated for either inclusion or exclusion from a liver transplant waiting 
list, respectively. 
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Tables 
Table 1a Study and demographic characteristics – Published Manuscripts 
Study ID Sample Size  
LT + LRT (All listed) 
Demographics and primary 
aetiology (%) 
Tumour Stage Before LRT 
(%) 
Interventions Child-Pugh  
(A/B/C) (%) 
Follow up (mo) 
Millonig et al. (18) 106 (116) Mean age 58 +/- 7 
HCV 43.2 
cTNM: G1 5.2, G2 53.5, G3 
28.4, G4 12.9 
TACE 52.6/44.8/2.6 Mean 37.2 +/- 30 
post LT 
Cucchetti et al. (19) 176 (315) Median age 57 
83.8% Male 
HCV 52.7 
cTNM: G1 53.7, G2 27.9, 
G3-G4a 16.8 
Multiple 
(TACE only 54.0%) 
- Median 24.3 (1-65) 
post LT 
Seehofer et al. (20) 71 85.3% Male 
HCV 35.6 
- TACE 44.6/55.4/0.0 78 +/- 6 
Otto et al. (22) 136 Median age 61 
78.7% Male 
Viral cirrhosis 53.9 
- TACE 55.1/25.7/19.1 Median 46.8 (0.56-
146.2) 
Lai et al.  (21) 422 Median age 60 
82.5% Male 
- Multiple  
(TACE only 64.7%) 
-/-/12.8 Minimum 24 
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HCV 45.5 
Shuster et al. (23) 58 Mean age 57.2 (34-70) 
89.7% Male  
HBV 43.1 
BCLC: A 24.1, B 74, C 1.7, 
D 0 
TACE 94.8/5.2/0.0 Mean 30.0 (0.36-
72.4) 
Kim et al. (24) 173 Mean age 56.9 (+/- 7.80) 
72.8% Male 
HCV 56.6 
- TACE 55.4/37.5/16.9 Mean 72 +/- 43.5 
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Table 1b Study characteristics – Conference Abstracts 
Study ID Sample Size  
LT + LRT (All listed) 
Follow up (mo) Interventions 
Sandroussi et al. (25)  130 Median 31 Multiple 
Sogawa et al. (27) 72 Minimum 48 Multiple 
De Simone et al. (26) 112 - TACE 
Mannina et al. (28) 31 Median 45.5 (0.13–66.1) SBRT 
Han et al. (29) 20 - Not stated 
Na et al. (30) 86 - Not stated 
Nicolini et al. (31) 59 - TACE 
Jiangyong et al. (32) 115 - TACE 
SBRT Stereotactic body radiation therapy;  
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Table 2a Study results – Published manuscripts 
Study ID [n] (m)RECIST Outcome 
(%) 
Recurrence Outcomes (5-year unless otherwise stated) Overall Survival Outcomes (5-year unless otherwise 
stated) 
Millonig et al. 
[106] 
CR 28.4, PR 56.9, SD+PD 6.6 - CR = 85.1%, PR = 63.9%, SD+PD = 51.4% (p=0.02 
for CR+PR vs. SD+PD) 
ITT: CR = 85.7%, PR = 66.2%, SD+PD = 19.3% 
(p<0.01 for CR vs SD+PD) 
Cucchetti et al. 
[176] 
CR 50, PR+SD+PD 50 Recurrence rate: CR = 5.5%; PR, SD or PD = 19.4% 
(p=0.02 for CR vs. PR or PD) 
p=0.098 for CR vs. PR+PD  
ITT: CR = 66.4%, PR+SD+PD = 45.0% (p=0.001) 
Seehofer et al. 
[71] 
CR+PR 25.4, SD 49.3, PD 25.4 Recurrence rate: 
MC-Out: p=0.047 for PD vs. CR+PR+SD 
MC-In: p=0.35 for PD vs. CR+PR+SD 
- 
Otto et al. 
[136] 
PD 12.5, SD+PR 87.5 RFS: PD 22%, SD+PR 88% (p<0.001); 
AP (HR 21.7 (CI 7.8-60.0), p<0.001) 
- 
Lai et al. [422] CR 28.7, PD 7.1 PD (HR 3.5 (CI 1.9-6.6), p<0.001) PD (HR 1.6 (1.0-3.1), p=0.04) 
Shuster et al. 
[58] 
CR 0, PR 48.2, SD 50, PD 1.7 - CR+PR = 89.9%, SD+PD = 34.3% (p=0.02) 
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Kim et al. 
[173] 
CR 23.7, PR 24.3, SD 27.7, PD 24.3  RFS: p=0.01 for CR+PR vs. SD+PD 
Recurrence rate: CR+PR 5.3%, SD+PD 17.6% (p=0.01) 
- 
AP Any Progression; CI Confidence Interval; ITT Intention-to-treat 
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Table 2b Study results – Conference abstracts 
Study ID [n] (m)RECIST Outcome 
(%) 
Recurrence Outcomes (5-year unless otherwise stated) Overall Survival Outcomes (5-year unless otherwise 
stated) 
Sandroussi et 
al. [130] 
- RFS: CR = 84%, PR = 61%, SD = 76%, PD = 41% 
(p=0.003) 
MC-In: CR+PR+SD = 72%, PD = 31% (p<0.001) 
MC-Out: CR+PR+SD = 76%, PD = 75% 
CR = 84%, PR = 64%, SD = 72%, PD = 52% (p=0.04) 
MC-In: CR+PR+SD = 71%, PD = 27% 
Sogawa et al. 
[72] 
CR 33.3, PR+SD 40.3, PD 26.4 
 
CR = 54.3%; PR+SD = 52.6%; PD = 52.6% (p=0.71) 
De Simone et 
al. [112] 
CR 53.6, PR+SD+PD 46.4 RFS: CR 100%; PR+SD+PD 86.8%  
(p=0.006 for CR vs. PR+SD+PD) 
- 
Mannina et al. 
[31] 
- RFS: (p>0.3)  (p>0.3) 
Han et al. [20] CR 30, PR 10, SD 45, PD 15 - No significant difference (p=0.43) 
Na et al. [86] - SD+PD independent risk factor for recurrence (p=0.04) - 
Nicolini et al. 
[59] 
- SD+PD independent risk factor for recurrence (OR=13.6, 
p=0.03) 
- 
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Jiangyong et 
al. [115] 
- RFS: CR+PR vs. SD+PD (p=0.009) 
 
CR+PR 75.0%, SD+PD 54.9% (p=0.02) 
 
OR odds ratio 
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Figures 
  
Figure 1 Study selection process 
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Abstract 
Background 
For a selected group of patients with hepatocellular carcinoma (HCC), liver transplantation 
represents the best chance of cure. Organ shortages necessitate an efficient allocation of 
resources and careful prioritisation on the transplantation waiting list. Selection criteria that 
use dynamic variables may improve organ allocation and outcome post-transplantation. 
Methods 
We retrospectively reviewed all patients at our centre with HCC who were listed for liver 
transplantation (LT) from 2002 to 2016 inclusive. We analysed the tumour response to 
locoregional therapy (LRT) as per the modified Response Evaluation Criteria in Solid 
Tumours (mRECIST). We also recorded serum alpha-fetoprotein (AFP) levels to determine 
peak and gradient. Primary outcome was overall survival (OS), with secondary outcomes 
recurrence-free survival (RFS), and predictors of waiting list drop-off. 
Results 
A total of 219 patients were listed for LT, with 156 of those transplanted. Out of those 
transplanted, 90 were suitable for mRECIST analysis after receiving LRT. Intention-to-treat 
analysis on all patients listed demonstrated that, on multivariate analysis, peak serum AFP 
> 1,000ng/mL on the waiting list was significantly associated with a decrease in OS 
(p=0.021); however, mRECIST progressive disease (PD) was not (p=0.12). Peak serum AFP 
levels > 200ng/mL were significantly associated with a reduced RFS after LT (p=0.019); 
mRECIST PD was not (p=0.54). In patients with PD, there was a significant difference in 
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mean percentage change in target lesions between those transplanted and not (-35.37 vs 
14.92% respectively, p=0.02). 
Conclusions 
Peak serum AFP levels were significantly associated with a reduced OS from date of listing 
and a reduced RFS after LT and may be considered in transplant decision making. Despite 
progressive disease, acceptable post-transplant RFS can be achieved in patients with a 
good response to LRT in target lesions or a peak serum AFP < 200ng/mL.  
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Introduction 
For a selected group of patients with hepatocellular cancer (HCC), liver transplantation (LT) 
represents the best chance of cure. Transplantation not only removes the primary lesion, it 
also removes the diseased liver that provides both a fertile ground for the development 
and growth of new disease, and potentially small intrahepatic metastases. Organ 
shortages necessitate efficient allocation of resources and careful selection of patients to 
be placed on a recipient waiting list. Hence, any improvements in predicting survival based 
on pre-transplant factors can assist in the allocation of resources and lead to improved 
outcomes for a large cohort of patients. 
Appropriate selection and prioritisation of patients forms the cornerstone of any 
transplantation service. Mazzaferro et al. reported acceptable survival results for patients 
with limited disease burden (a single HCC lesion <5cm in size or 3 or fewer lesions with the 
largest <3cm in size) - the Milan Criteria (MC) (1). Since then, various groups have 
expanded MC with acceptable survival outcomes, such as the University of California, San 
Francisco (UCSF) criteria (2). Predicting survival post-LT based on pre-LT factors has been 
an area of interest for many years; however, definitive guidelines remain elusive (3). In 
recent years, interest has been shown in the effect that locoregional therapies have on 
long-term survival post-LT, with the view to using this information in determining a 
“biological selection” criteria to appropriately expand the purely morphologically based 
MC or UCSF criteria. Proxies acting for this biological criteria have been suggested by 
various groups, including serum alpha-fetoprotein (AFP) levels (4-7), neutrophil-to-
lymphocyte and platelet-to-lymphocyte ratios (8, 9), and response to pre-LT locoregional 
therapies (LRT) (10, 11). 
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In the context of LT, LRTs have been used as either a bridging strategy, to maintain a 
patient on a transplant waiting list, or a downstaging strategy, to make a patient eligible for 
transplant. Many different types of locoregional therapy exist, including transarterial 
chemoembolization (TACE), radiofrequency or microwave ablation (RFA/MWA) and 
percutaneous ethanol injections (PEI). These therapies can also be used on their own or in 
combination outside of the transplant setting in patients not suitable for transplantation or 
resection (12, 13). Treatment on the waiting list with LRT to avoid drop-off is 
recommended based on current evidence (14); however, no recommendation exists for 
using response to LRT as a predictor of post-transplant outcome (15).  
In this paper, we examine morphological and biomarker predictors of recurrence-free 
survival (RFS) and overall survival (OS) in our single centre experience. We seek to identify 
pre-transplant markers that can be used to modify patient selection in order to improve the 
allocation of donor organs.  
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Methods 
Patient Selection 
We retrospectively reviewed all consecutive adult patients listed for liver transplantation 
where hepatocellular carcinoma (HCC) was their primary indication from 2002 to 2016 
inclusive, at our single institution. We included all aetiologies for HCC. Pre-transplant LRTs 
recorded were transarterial chemoembolization (TACE), percutaneous ethanol injection 
(PEI) and radiofrequency or microwave ablation (RFA/MWA). TACE treatments included 
cisplatin or doxorubicin beads. No patient had selective internal radiotherapy or external 
beam radiotherapy as a bridging or downstaging strategy during this study period. If a 
patient had multiple transplants, we measured survival data from the first only. If a lesion 
was initially reported as suspicious for HCC and later confirmed as such either 
radiologically or on explant pathology, it was considered HCC from the time of initial 
report. Exclusion criteria were HCC discovered during the waiting period after listing for 
another indication, incidental HCC or cholangiocarcinoma (CC) found on explant 
pathology, surgical resection prior to LT, a follow-up period of less than 1 year, and living 
donor transplants. 
Listing for transplantation and use of locoregional therapies 
At our centre, allocation of donor organs is guided by the Transplant Society of Australia 
and New Zealand (TSANZ) (16). Transplant eligibility for patients with HCC is by the 
radiological UCSF criteria; however, patients are removed from the waiting list if follow up 
imaging indicates advancement beyond UCSF. We do not solely use MELD or variations 
such as tumour MELD for prioritisation; ultimate allocation is discretionary and 
prioritisation is by consensus at a weekly multidisciplinary meeting involving both 
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transplant physicians and surgeons. Typical reasons to prioritise HCC patients include: 
time waiting, persistent evidence of arterialisation of tumours despite therapy, and the 
inability to approach lesions with LRT because of their anatomical location and/or arterial 
supply. We routinely treat HCC with LRT prior to formal listing on the transplant list as 
either a maintenance or downstaging therapy, and in this cohort, all but 19 patients who 
received pre-transplant LRT started it prior to listing. The selection for LRT is performed at 
a Multi-Disciplinary-Team meeting attended by transplant hepatologists, diagnostic and 
interventional radiologists and transplant surgeons.  In general, tumours thought to be 
amenable to ablation are treated with such either as a primary treatment or after TACE 
which has not only a synergistic effect but can help to mark the lesion for subsequent RFA 
or MWA.  TACE is performed in preference to ablation when there are more than 2 lesions, 
there is ascites or when the positions of the tumours would make ablation unsafe or 
ineffective. Patients with small and only ‘suspicious’ lesions and an expected short waiting 
time for transplant are sometimes observed with imaging every 3 months and only treated 
pre-transplant if there is evidence of progressive disease. 
Assessment of radiological response 
We assessed radiological response as per the modified Response Evaluation Criteria for 
Solid Tumours (mRECIST)(17). In mRECIST analysis, overall response is a combined 
assessment of target lesions, non-target lesions, and new lesions. The appearance of a 
new lesions declares progressive disease regardless of the response of target and non-
target lesions. For patients to be eligible for mRECIST sub-group analysis, appropriate 
imaging as per mRECIST had to have been performed prior to the first LRT and again prior 
to transplantation (or drop-off, if not transplanted) but after the final LRT. The first LRT may 
have been performed prior to formal listing on the transplant wait list. The most recent 
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imaging before LT or drop-off must have been within 6 months of the event. All imaging 
was independently reviewed by a specialist radiologist (YK), who was blinded to LRT and 
subsequent outcome. All images were viewed on diagnostics Picture Archival Computer 
System (PACS) and studies from the same patient were reviewed side-by-side to allow 
comparison and correlation of lesions across two studies. The number and size of lesions, 
both target and non-target, were measured in accordance with mRECIST criteria. In the 
event images were not archived for review, but written reports were available, the written 
reports were used to determine mRECIST measurements and responses. 
Biochemical markers 
We collected the following biochemical markers: Model for End-Stage Liver Disease 
(MELD) score at LT/ drop-off; serum AFP values at time of listing, first LRT, LT/drop-off 
and the peak value on the waiting list. All serum AFP values are ng/mL. Serum AFP 
gradient was then calculated from the first reading to the pre-LT/drop-off value, giving 
ng/mL/month units. 
Explant information 
We recorded tumour size, number, percentage of necrosis and the presence of 
microvascular invasion (MVI), lymphatic invasion (LI) and perineural invasion (PNI) from 
explant histopathology. 
Subgroup analysis 
We separately analysed 3 main subgroups: an intention-to-treat (ITT) analysis of all 
patients listed with the intended treatment being liver transplantation (Group L); all 
transplanted patients (Group T); and an assessment of transplanted patients who 
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underwent LRT and where appropriate imaging enabled an mRECIST analysis (Group MT). 
Within Groups L and MT, we further analysed the difference between patients inside and 
outside radiological MC and UCSF (MC-IN/OUT and UCSF-IN/OUT respectively) at time of 
first LRT and transplant/drop-off, patients who were within criteria and then advanced out 
(MC-A, UCSF-A), and those who were outside criteria and were downstaged (MC-D, 
UCSF-D). Group T analysis was primarily for biochemical markers such as serum AFP. 
Outcomes 
Primary outcome was overall survival (OS) from date of listing. Secondary outcomes were 
recurrence-free survival (OS) from transplant, as diagnosed on follow-up imaging after LT, 
and listing and waiting list drop-off.  
Statistical Analysis 
Kaplan-Meier analysis was used for survival with the log-rank test statistic used to 
determine differences in survival distribution. Univariate and multivariate Cox regression 
was used to generate hazard ratios, and binary logistic regression was used for odds 
ratios. For non-normally distributed data, Mann-Whitney U tests were used for mean 
comparisons. Linear regression was used for comparisons with continuous data. All 
statistics were generated using IBM SPSS Version 24 with p<0.05 considered statistically 
significant.  
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Results 
Patient characteristics and response to treatment 
Figure 1 shows a breakdown of patient groups. A total of 219 patients were included 
(Group L). One-hundred and fifty-six (156) patients underwent LT (Group T), and of those, 
122 patients underwent pre-transplant LRT. Out of them, 90 had imaging which enabled 
mRECIST analysis and form Group MT. Those who were transplanted but not eligible for 
Group MT did not have follow up imaging prior to LT in the required timeframe (e.g. were 
transplanted prior to routine follow-up imaging after LRT). Of the patients not transplanted 
after receiving LRT, 45 were able to undergo mRECIST analysis. Sixteen (16) patients died 
whilst on the waiting list. On independent, retrospective analysis of pre-transplant imaging 
it was shown that 4 patients in Group MT were transplanted when outside UCSF. Patient 
characteristics, imaging and explant information, are outlined in Table 1. There was no 
significant difference in sex or age distribution between those transplanted and those that 
were not.  
Intention-to-treat Analysis 
Group L comprises all patients listed for LT with HCC as their primary indication (n=219). 
Of these, 178 patients underwent LRT. OS at 1 and 5 years was 81.5% (95% CI 79.0-84.0) 
and 60.7% (95% CI 57.34-64.06), respectively. Uni- and multivariate Cox regression 
results for OS from listing are demonstrated in Table 2. On univariate analysis, OS was 
significantly reduced by an aetiology of HCV (HR=1.62, 95% CI 1.01–2.59, p=0.046), a 
peak serum AFP > 1000 (HR=1.95, 95% CI 1.09 – 3.48, p=0.024), and having > 3 tumours 
on final imaging prior to LT/drop-off (HR=3.48, 95% CI 1.82 - 6.63, p<0.001), whilst being 
MC-IN at LT/drop-off significantly increased OS (HR=0.41, 95% CI 0.24-0.70, p=0.001). 
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Figures 3 and 4 show the OS curve using Kaplan-Meier analysis for serum AFP > 1000 and 
MC-IN at LT/drop-off, respectively. On multivariate analysis, only having a peak serum 
AFP > 1000 and > 3 tumours on final imaging were significantly associated with a 
decreased OS (HR=2.04, 95% CI 1.02 - 4.05, p=0.043 and HR=1.28, 95% CI 1.10 - 1.50, 
p=0.001). In those patients where mRECIST analysis was possible (n=135), there was not a 
significant difference in OS for patients with progressive disease (PD) compared to other 
categories (mean 39.63 vs 45.60 months, p=0.12, Figure 5). When analysing all patients 
regardless of whether they received LRT or not, patients who were initially MC-OUT and 
were downstaged to MC-IN had a significantly increased OS over those that remained 
MC-OUT (25.0 vs 56.9%, p=0.04). There was not a statistically significant decrease in OS 
when comparing patients who were initially MC-IN then advanced to MC-OUT compared 
to those that remained MC-IN (48.9 vs 66.0%, p=0.13). There was no significant difference 
in OS between Group L patients who received LRT and those who did not (p=0.57).  
Analysis of wait times and waiting list drop-off 
For Group L patients (i.e. all those listed for transplant), the odds ratio (OR) for drop-off 
from the waiting list was 2.20 with PD after LRT (95% CI 1.06 - 4.58, p=0.035), and 2.99 
with a peak serum AFP > 200 (95% CI 1.48 – 6.03, p=0.002). In patients who dropped off 
the waiting list, there was a significant increase in time to drop-off in patients who received 
LRT compared to those that did not (mean time 33.83 vs 17.36 months, p=0.023), and a 
longer waiting time was significantly associated with an increased OS from listing (HR 
0.89, 95% CI 0.85–0.93, p<0.001). Furthermore, a MELD > 15 at drop-off significantly 
decreased OS (HR 2.37, 95% CI 1.34–4.19, p=0.003). Patients who dropped off also had a 
significantly higher mean MELD score compared to those transplanted (20.5 vs 15.35, 
p=0.001 on Mann-Whitney U test). 
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Analysis of transplanted patients 
One hundred and fifty-six patients were transplanted (Group T), with 122 of those receiving 
LRT. Group MT comprises the 90 patients where radiological disease progression was 
assessable. RFS at 5 years was 91.8% (95% CI 89.57 - 96.50%). In Group T, peak serum 
AFP > 200 was significantly associated with a decrease in RFS on univariate Cox 
regression and Kaplan-Meier (HR 3.90, 95%CI 1.14 - 13.34, p=0.019, Figure 6). There was 
no significant difference in RFS or OS between those who received LRT and those that did 
not (RFS p=0.26, OS p=0.44 on Kaplan-Meier). Length of waiting time also was not 
significantly associated with RFS or OS (p=0.68 and 0.78 on Cox regression, respectively). 
Group MT uni- and multivariate Cox regression results for RFS are shown in Table 3. In our 
cohort, there was no significant difference in RFS between patients who had PD compared 
to non-PD (Kaplan-Meier RFS p=0.54, Figure 7), or CR compared to non-CR (RFS p=0.84 
on Kaplan-Meier). A peak serum AFP > 1000 was not significantly associated with RFS on 
univariate analysis for Group MT; however, on multivariate analysis it was significantly 
associated with a decreased RFS (HR 31.34, 95%CI 2.88 – 348.64, p=0.005). No variables 
were associated with OS on uni- or multivariate analysis. 
Analysis of Group MT patients according to Milan and UCSF Criteria 
In Group MT patients (i.e. those transplanted after LRT where mRECIST analysis with 
possible), significant improvements in RFS were seen with patients within UCSF at first 
LRT, however numbers involved are small with only n=5 patients UCSF-OUT (RFS at 5 
years 94.3% vs 30.0%, p<0.001). Being MC-IN at first LRT was not significantly 
associated was an improvement in RFS (93.4% vs 78.8%, p=0.074), or OS (p=0.46). There 
was no statistically significant difference with RFS for patients originally MC-IN who then 
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became MC-OUT, but remained UCSF-IN, compared to those that remained MC-IN 
(p=0.59). Likewise, for patients originally MC-OUT there was no statistically significant 
difference between those downstaged to MC-IN and not (p=0.46). Furthermore, there was 
no statistically significant association with RFS comparing patients in and out of MC at the 
last imaging prior to LT (p=0.71). 
Analysis of patients with mRECIST progressive disease 
Figure 3 demonstrates differences between patients with mRECIST PD and non-PD, as well 
as between those with PD who were transplanted and not. As previously mentioned, our 
group had no significant difference in RFS post-LT for patients with mRECIST PD, or a 
significant difference in OS from listing on ITT analysis.  When analysing the difference in 
percent change in tumour response between patients who dropped-off and were 
transplanted, there was a significant difference in the mean change of mRECIST target 
lesions (14.92 vs -35.37% respectively, p=0.02) and mean overall change in total tumour 
burden (77.45 vs 36.18% respectively, p=0.025). There were also significant differences 
between mean peak serum AFP (5903.62 vs 126.65 respectively, p=0.002) and mean 
serum AFP at time of LT/drop-off (1627.92 vs 78.30 respectively, p=0.04). There were no 
significant differences in the above variables when comparing patients with non-PD who 
were transplanted and dropped-off. 
Analysis of explant histopathological characteristics 
On explant histopathology, microvascular invasion (MVI), lymphatic invasion (LI) and 
perineural invasion (PNI) were not significantly associated with RFS for all transplanted 
patients (i.e. Group T) (p=0.28, 0.87 and 0.14 on Cox regression, respectively). However, in 
patients who did not receive LRT, the presence of MVI did significantly impact RFS 
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(p=0.023) – although numbers are small with 1 recurrence in 5 patients. No morphological 
explant data (e.g. radiological MC) was significantly associated with RFS or OS.   
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Discussion 
Since the introduction of the Milan Criteria in 1996 there has been an ongoing effort to 
expand and refine the selection criteria for transplantation in patients with HCC. Traditional 
selection criteria rely on a static reading of tumour morphology, but in recent years there 
has been growing interest in in dynamic markers that may represent tumour biology and 
hence assist in selecting the most appropriate patients for transplant (18). Tumour 
response to pre-transplant LRT and biomarkers such as serum AFP have been proposed 
as predictors of post-transplant survival (10, 11, 19).  
Response to pre-transplant locoregional therapy 
mRECIST is one criteria that can be used for measuring tumour response. In a systematic 
review analysing the relationship between (m)RECIST and survival, our group found that 
several investigators identified statistically significant results, most notably between PD 
and a reduced RFS (11, 20-22). With our selection criteria, which is based on radiological 
UCSF and allows exclusion based on progression outside of UCSF criteria on the waiting 
list, we did not find a significant association between post-LT RFS or OS and mRECIST 
PD. When performing an intention-to-treat analysis on all patients listed for LT, OS from 
listing was not significantly associated with mRECIST PD after LRT, however it was 
associated with a significant risk for waiting list drop-off. In order to further classify those 
patients who had PD and still had acceptable RFS and OS post-transplant, we analysed 
differences between those who dropped-off and were transplanted (Figure 2). Of note, 
when assessing percentage change in the mRECIST target lesions, those transplanted had 
a mean decrease in size, where those who dropped-off had a mean increase, with a 
significant difference between the two groups. For a patient to have mRECIST PD after a 
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decrease in target lesion size they must either have the development of new lesions or be 
assessed with PD in non-target lesions. Given our selection criteria, it can be concluded 
that patients with progressive disease can have acceptable survival after transplant if they 
have a response to LRT in their target lesions and remain within UCSF criteria.  
In our study, being within MC at final imaging prior to LT did not have a significant 
association with survival for Group MT patients (those transplanted after LRT where 
mRECIST analysis was possible). In contrast, Otto et al. have demonstrated that MC on 
imaging after the last LRT prior to LT was significantly predictive of recurrence post-LT 
(21). In their protocol, the authors did not exclude patients from LT due to morphological 
progression, which may explain the difference. We also demonstrated that there was no 
significant difference in RFS post-transplant comparing patients who advanced from MC-
IN to MC-OUT (whilst remaining UCSF-IN) with those who remained MC-IN. This result 
supports the use of UCSF as selection criteria over the more restrictive MC and suggests 
some advancement of disease can be tolerated. On intention-to-treat analysis, patients 
initially MC-OUT who were then downstaged to MC-IN had significantly improved OS 
compared to those who remained MC-OUT. Current EASL guidelines are equivocal over 
the use of downstaging due to a lack of prospective data showing survival benefit (23). In 
addition, the most recent AASLD guidelines do suggest downstaging to MC, albeit with 
acknowledgement that the level of evidence is very low (24). Our data suggests that 
attempts at downstaging should be undertaken in patients beyond MC but within UCSF. 
In this study, we did not demonstrate a difference in RFS or OS after transplant in patients 
who received LRT compared to those who did not. This may be because those who 
received LRT and still had tumour progression of target lesions dropped off the transplant 
list. LRT did maintain patients on the transplant list longer, which aligns with current 
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guidelines suggesting that it should be used to control tumour if waiting times are 
expected to be greater than 6 months (14, 23, 24). In a recent meta-analysis of current 
evidence for pre-transplant LRT, the authors conclude that there are non-statistically 
significant trends in reduced waiting list drop-off and improved post-transplant outcomes 
in patients treated with LRT; however, no RCTs were identified and the available 
comparative studies had a high risk of selection bias (25). In our cohort, patients who did 
not undergo LRT and also had MVI on explant histopathology had a significantly worse 
recurrence-free survival compared to those who did not; however, this was a small cohort 
of patients. It may suggest that LRT has a protective nature, although larger studies would 
be needed to clarify this. 
Serum Alpha-fetoprotein 
Serum alpha-fetoprotein has been investigated in many retrospective cohort analyses and 
in many different permutations, using both static and dynamic variables. It has been 
suggested it is surrogate for microvascular invasion (26). Merani et al. demonstrated that 
the last serum AFP reading prior to LT independently predicted survival, unlike AFP at 
listing or AFP changes (27). Several authors have shown similar results, although no 
definitive cut-off has been agreed upon, with authors varying from 66 to 1,000ng/mL (6, 
28-30). In contrast, Duvoux et al. showed that serum AFP at listing was an independent 
predictor of recurrence, with those with AFP level > 100ng/mL independently affecting 
recurrence (31). Several authors have shown that serum AFP slope can predict recurrence, 
using cut-off values of >15ng/mL/month and >7.5ng/mL/month (11, 26, 32). Our results 
support other internationally published data that suggests high serum AFP values should 
be considered in transplant decision making due to a significantly higher recurrence rate. 
We use peak serum AFP over the entire pre-transplant phase, hence incorporate both AFP 
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at listing and the last results prior to LT, as well as account for peaks between episodes of 
LRT. Our data suggests that a cut-off of peak serum AFP > 1000ng/mL may be 
appropriate as an exclusion criterion, as this led to a significantly reduced ITT OS from 
time of listing, and was associated with a significantly reduced RFS after LT. There was a 
significant difference in mean serum AFP between patients with PD who were transplanted 
and those that dropped-off, and when performing an ITT analysis on all patients with PD 
there was a significant decrease in OS with peak serum AFP > 200. In addition to 
monitoring response of the target lesions, as discussed above, our data suggests that 
patients with PD can continue to be considered for transplant if their serum AFP remains 
low, i.e. below 200ng/mL. 
Our study has some limitations of a retrospective, single centre study. Our selection 
criteria already take into account progression on the waiting list, and hence our post-
transplantation analysis represents a highly selected cohort. Many patients who underwent 
LT were not included in the mRECIST analysis owing to transplant occurring prior to follow 
up imaging after LRT (i.e. within 3 months), reducing the power of the study. Overall 
recurrence rates were low, further contributing to this. We purposefully include all 
modalities of LRT to increase the patient cohort, without comment on relative efficacies of 
these treatments or when one is preferable to another. 
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Conclusions 
Liver transplantation centres rely on appropriate selection criteria to distribute a scarce 
resource in an optimal manner. Since the introduction of the Milan Criteria many 
investigators world-wide have identified acceptable expansions of that criteria as well as 
additional markers that may assist in patient selection, such as radiologically progressive 
disease or serum AFP. In our study, peak serum AFP levels above 1,000ng/mL 
significantly reduced OS from date of listing on intention-to-treat analysis. In patients who 
were transplanted, those with a peak serum AFP > 200ng/mL had a significantly reduced 
RFS. Even with mRECIST PD, acceptable post-transplant survival was obtained in patients 
who had a decrease in size of mRECIST target lesions and had peak serum AFP levels < 
200ng/mL. There was no significant difference in RFS or OS for patients who were 
transplanted after PD and those with non-PD. Data from our single-centre experience adds 
to growing evidence that serum AFP levels are a useful marker for identifying patients at 
risk of a poor recurrence-free survival post-transplant, and hence should be considered in 
transplant decision making. 
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Figures 
 
Figure 2 Patient groups. 
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Figure 3 Differences between patients with mRECIST PD and non-PD criteria, comparing transplant and 
waiting list drop-off.  
  
 74 
 
 
Figure 4  Intention-to-treat overall survival of all patients included from date of listing 
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Figure 5 Intention-to-treat overall survival from date of listing for all patients, peak serum AFP > 1000ng/mL 
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Figure 6 Intention-to-treat overall survival for patients listed who underwent LRT, comparing between inside 
and out of Milan Criteria at time of transplant/drop-off 
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Figure 7 Intention-to-treat overall survival from date of listing for all patients with mRECIST analysis, PD vs 
non-PD 
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Figure 8 Recurrence-free survival for all transplanted patients, peak serum AFP > 200ng/mL.  
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Figure 9 Recurrence-free survival for patients who were transplanted after locoregional therapy and were 
eligible for mRECIST analysis, comparing patients with PD against non-PD 
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Tables 
Table 1 Patient, pathological and radiological characteristics 
Variable Group L Group T Group MT 
n 219 156 90 
Age (years) 56 (26-69) 56 (26-69) 56 (33 - 69) 
Sex - Male [n (%)] 188 (85.8) 131 (84.5) 75 (83.3) 
Aetiology [n (%)]    
HCV 130 (59.4) 88 (56.4) 54 (60.0) 
HBV 31 (14.2) 29 (18.6) 16 (17.8) 
Alcohol 33 (15.1) 22 (14.1) 9 (10.0) 
Cryptogenic 3 (1.4) 2 (1.3) 1 (1.1) 
NAFLD/NASH 9 (4.1) 5 (3.2) 3 (3.3) 
PSC 4 (1.8) 4 (2.6) 3 (3.3) 
PBC 1 (0.5) 1 (0.6) 1 (1.1) 
AIH 3 (1.4) 3 (1.9) 2 (2.2) 
Haemochromatosis 2 (0.9) 2 (1.3) 1 (1.1) 
A1ATD 2 (0.9) 0  0 
Other 1 (0.5) 0 0 
Waiting time (months) - 5.09 (0-41.26) 6.48 (0 - 41.26) 
Time to waiting list drop-off (months) 6.44 (0.16 – 34.68) - - 
Follow up (months) 33.63 (0.0 – 176.84) 56.28 (0.03 – 176.84) 55.12 (0.03 – 170.10) 
Biochemical markers 
MELD  15 (6-48) 14 (6-42) 14 (6-39) 
Serum AFP gradient  -0.023 (-1024 – 5442) 0.0 (-1024 – 524.22) -0.03 (-1024 – 524.22) 
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Serum peak AFP  21.93 (1.93-97236) 17.05 (1.93.- 4721.69) 16.93 (1.93-4721.69) 
Serum AFP at transplant - 7.6 (1.2-1041) 7.7 (1.2-1041) 
Serum AFP at drop-off 13.2 (1.4 – 80706) - - 
LRT 
Received LRT [n (%)] 178 (81.3) 122 (78.2) 90 (100) 
Total number of treatments 2 (0-11) 2 (0-11) 2 (0-9) 
TACE n, median (range) 165, 2 (0-10) 113, 2 (0-10) 86, 2 (0-9) 
PEI n, median (range) 28, 1 (1-3) 20, 1 (1-3) 15, 1 (1-3) 
RFA/MWA n, median (range) 48, 1 (1-3) 34, 1, (1-3) 20, 1 (1-3) 
Imaging variables 
Patients eligible for mRECIST analysis (n) 163  90 
MC-IN (prior to first LRT) 138 (84.7)  75 (83.3) 
UCSF-IN (prior to first LRT) 154 (95.4)  85 (94.4) 
MC-IN (prior to transplant/drop-off) 131 (80.4)  82 (91.1) 
UCSF-IN (prior to transplant/drop-off) 140 (85.9)  86 (95.6) 
MC-D 17   13 
UCSF-D 6  5 
MC-A 26  8 
UCSF-A 21  4 
mRECIST 
CR 40 (24.5)  30 (26.5) 
PR 26 (16.0)  20 (17.5) 
SD 29 (17.8)  22 (19.3) 
PD 68 (41.7)  42 (36.8) 
Explant variables 
Number of tumours  2 (1-18) 2 (1-10) 
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Total size (mm)  40 (8-210) 40 (8-210) 
% necrosis  31.87 (0-100) 27.42 (0-100) 
MC-IN  84 (54.5) 62 (54.4) 
UCSF-IN  102 (66.2) 75 (65.8) 
MVI  17 (11) 14 (12.3) 
LI  14 (9.1) 11 (9.6) 
PNI  3 (1.9) 2 (1.8) 
Group L All patients listed for transplant, Group T All transplanted patients, Group MT All patients transplanted after LRT and 
eligible for mRECIST analysis.  
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Table 2 Univariate and multivariate Cox regression analysis for overall survival from date of listing for all 
patients 
Variable p HR 95% CI 
   Lower Upper 
Univariate 
Sex 0.67 1.16 0.60 2.24 
HCV vs others 0.046 1.62 1.01 2.59 
Waiting time 0.083 0.97 0.94 1.00 
Age 0.22 1.02 0.99 1.06 
MELD > 15 at LT/drop-off 0.073 1.49 0.96 2.31 
LRT 0.28 1.40 0.76 2.59 
Serum AFP at LT/drop-off 0.067 1.00 1.00 1.00 
Peak Serum AFP > 1000 on waiting list 0.024 1.95 1.09 3.48 
Serum AFP gradient on waiting list 0.03 1.00 1.00 1.00 
MC at LRT/listing 0.40 0.78 0.43 1.40 
MC at LT/drop-off 0.001 0.41 0.24 0.70 
UCSF at LRT/listing 0.32 0.69 0.33 1.43 
UCSF at LT/drop-off <0.001 0.27 0.16 0.48 
PD vs non-PD 0.12 1.54 0.89 2.66 
Number of tumours >3 on final imaging prior to LT/drop-off <0.001 3.48 1.82 6.63 
Total tumour size on final imaging prior to LT/drop-off 0.49 1.00 0.99 1.01 
Multivariate 
Sex 0.72 0.87 0.42 1.81 
Age 0.14 1.03 0.99 1.08 
HCV vs others 0.18 1.49 0.83 2.65 
Waiting time 0.10 0.97 0.94 1.01 
MELD > 15 at LT/drop-off 0.24 1.39 0.81 2.38 
Peak Serum AFP > 1000 on waiting list 0.043 2.04 1.02 4.05 
LRT 0.12 1.93 0.84 4.44 
MC at LT/drop-off 0.51 0.79 0.40 1.58 
Number of tumours > 3 on final imaging prior to LT/drop-off 0.001 1.28 1.10 1.50 
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Table 3 Univariate and Multivariate Cox Regression for RFS after transplant for all patients who received LRT and mRECIST analysis 
Univariate 
Variable p HR 95% CI 
   Lower Upper 
Sex 0.46 0.04 0.00 209.49 
Age 0.96 1.00 0.90 1.11 
HCV 0.50 1.77 0.34 9.11 
Waiting time 0.86 1.01 0.93 1.10 
MELD > 15 0.63 0.66 0.13 3.43 
Serum AFP > 200 at transplant 0.26 2.58 0.5 13.33 
Peak Serum AFP > 1000 0.10 3.90 0.76 20.13 
Serum AFP Gradient 0.33 1.00 1.00 1.00 
MC at first LRT/listing 0.10 0.28 0.06 1.25 
UCSF at first LRT/listing <0.001 0.06 0.01 0.26 
MC at transplant 0.71 0.67 0.08 5.56 
CR vs non-CR 0.84 0.85 0.16 4.37 
PD vs non-PD 0.54 1.59 0.36 7.10 
Total tumour volume on 
imaging 
0.92 1.00 0.96 1.03 
Explant number of tumours 0.14 1.23 0.94 1.61 
Explant total tumour burden 
(mm) 
0.32 1.01 0.99 1.03 
Explant necrosis % 0.50 0.99 0.97 1.02 
Explant MC 0.21 0.35 0.07 1.79 
Explant UCSF 0.16 0.34 0.08 1.54 
Explant MVI 0.55 1.92 0.23 16.14 
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Explant LI 0.64 0.04 0.00 >100 
Explant PNI 0.84 0.05 0.00 >100 
Multivariate 
Variable p HR 95% CI 
   Lower Upper 
Sex 0.98 0.0 0.0 inf 
Age 0.34 1.11 0.89 1.39 
HCV 0.63 0.52 0.035 7.52 
Waiting time 0.29 1.08 0.94 1.24 
MELD > 15 0.35 3.32 0.26 41.98 
Peak Serum AFP > 1000 0.013 108.62 2.71 4346.65 
UCSF at first LRT/listing 0.003 0.003 0.0 0.14 
MC at transplant 0.30 0.13 0.003 5.94 
PD vs CR/PR/SD 0.53 2.24 0.18 27.52 
Explant MC 0.15 0.21 0.026 1.71 
Explant MVI 0.87 0.79 0.044 14.09 
Explant Necrosis > 50% 0.83 0.75 0.053 10.55 
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Appendix 1: Unpublished data 
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Predicting survival post-transplantation using inflammatory 
markers 
Introduction 
In addition to radiological morphology and serum alpha-fetoprotein changes, there has 
been interest in the role that inflammatory markers can play in predicting survival post-
transplantation. In particular, neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios 
(NLR and PLR, respectively) have been investigated in various centres internationally (1, 2). 
This appendix contains unpublished data from our retrospective cohort study that forms 
Chapter 2, using the same patient groups (L and T) as outlined in the Methods section of 
that paper (page 55). 
Results 
Patient characteristics 
Patient characteristics can be reviewed in Table 1, Chapter 2 (page 80) 
Intention-to-treat analysis of all patients listed for transplant 
There was no significant difference in overall survival (OS) on Kaplan-Meier for NLR > 5 or 
PLR > 150 for Group L patients. 
Analysis of wait times and drop-off 
Group L patients with NLR > 5, PLR > 150 had significantly increased odds ratios (OR) for 
dropping-off the waiting list (OR=2.35, 95% CI 1.27 – 4.38, p=0.007 and OR=2.17, 95% CI 
1.08 – 4.36, p=0.03, respectively). There was a significant difference between mean NLR in 
patients who dropped-off compared to those transplanted (8.17 vs 4.94, respectively, 
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p=0.018 on Mann-Whitney U test). In patients who did drop-off, NLR had a significant 
association with decreased OS (HR 1.03, 95% CI 1.00 – 1.05, p=0.033).  
Analysis of all transplanted patients 
For Group T patients, PLR was significantly associated with an increased OS on univariate 
Cox regression; however, the effect is minimal (p=0.047, HR 0.985 95% CI 0.97-1.0). The 
Kaplan-Meier curve is shown in Figure 1. PLR was not significantly associated with RFS 
(p=0.13); NLR was not significantly associated with either RFS or OS (p=0.20 and 0.073, 
respectively). 
Discussion 
After initially demonstrating that an NLR > 5 was an independent predictor of recurrence in 
patients with colorectal cancer liver metastases, Halazun et al. subsequently demonstrated 
that an elevated pre-transplant NLR significantly reduced recurrence-free survival (3, 4). 
Limaye et al. demonstrated that an elevated NLR both at time of diagnosis and at 
operation were associated with a decrease in OS and RFS (5). When analysing living-
donor liver transplants, Motomura et al. showed similarly significant results for RFS, whilst 
also demonstrating that peritumoral IL-17 levels were also significantly elevated in the 
high-NLR group without a corresponding increase in VEGF or IL-8 - major angiogenesis 
factors. They conclude the elevated NLR promotes recurrence via an inflammatory 
environment, rather than angiogenesis alone. Lai et al. showed that elevated NLR was a 
predictor of drop-off from the waiting list but not recurrence after LT, however they did 
demonstrate that PLR predicted recurrence (2). In contrast, Parisi et al. did not 
demonstrate a significant association between inflammatory markers and recurrence post-
LT (6). In our transplanted cohort, there was no significant difference in RFS or OS in 
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patients with an elevated NLR > 5. However, on ITT analysis NLR > 5 and PLR > 150 were 
associated with a greater risk of drop-off from the waiting list; there was also a significantly 
different mean NLR between those transplanted and not. Our findings do support those of 
Lai et al. in showing that elevated NLR may be a predictor of drop-off. Our result 
demonstrating that an elevated PLR > 150 gives a statistically significant RFS advantage 
runs contrary to previously published work (2), and is of uncertain clinical significance 
given its small HR. 
Conclusions 
Data from our single-centre experience supports previously published data showing that 
NLR > 5 may be used to identify patients at risk of dropping-off from the wait list. 
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Figures 
 
Figure 1 Overall survival for transplanted patients with PLR > 150. PLR platelet-to-lymphocyte ratio 
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Appendix 2: Additional publications completed during 
candidature for this thesis, but not forming part of it 
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Abstract 
Background 
Complex en-bloc multivisceral resections for upper abdominal tumours are rare, as is data 
on short-term complications. This study describes short-term complications and 
outcomes following radical surgical approaches to patients with large tumour burden. 
Methods 
Consecutive patients who underwent en-bloc upper abdominal resections for tumours 
involving multiple organs were identified and retrospectively reviewed. Primary outcomes 
were short-term complications as per the Clavien-Dindo Classification and Comprehensive 
Complication Index. Secondary outcomes were overall survival and recurrence-free 
survival.  
Results 
We identified 34 consecutive patients who underwent resection from 2012 to 2016. A 
variety of tumours were included, the most common being renal cell carcinoma. Mean 
(range) Clavien-Dindo Classification score was 1.74 (0,6), with mean (range) 
Comprehensive Complication Index of 23.18 (0, 78). Statistically significant associations 
with Clavien-Dindo Classification were ICU readmission, operating theatre takeback and 
IVC involvement in the resection. In addition to ICU readmission and theatre takeback, 
statistically significant predictors of Comprehensive Complication Index were operation 
time, ileal, adrenal, and IVC resection, and biliary reconstruction. There were no peri-
operative deaths. Lymphatic invasion (p=0.016), liver resection (p<0.001), and duodenal 
resection (p=0.025) had a statistically significant association with reduced recurrence-free 
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survival. Presence of metastatic disease (p=0.047) and operation time (p=0.021) were 
significantly associated with decreased overall survival.  
Conclusion 
In appropriately selected patients, en-bloc multivisceral resection of upper abdominal 
tumours is safe. Complications were not statistically associated with patient factors, 
however, were associated with adrenal, ileal and IVC resection and biliary reconstruction. 
Short term recurrence-free and overall survival are acceptable. 
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Introduction 
Complex multivisceral resections (MVR) for upper abdominal tumours are rare. Advances 
in surgical technique and equipment, intensive care services and anaesthesia have made 
these increasingly possible. Achieving an R0 resection remains the central goal of surgical 
oncology however the decision to operate must balance the potential survival reward with 
that of significant post-operative morbidity. This study describes the short-term 
complications and survival outcomes following radical en-bloc surgical approaches to 
patients with large tumour burden.  
Methods 
We performed a retrospective cohort analysis of consecutive patients who underwent en-
bloc upper abdominal multivisceral resection (MVR). Patients were identified using the 
surgeons’ records and the resection targets confirmed against hospital operative reports 
and histopathology. We included only patients who underwent en-bloc resection, thus, for 
example, patients who had colorectal cancer (CRC) primary resections with non-
contiguous liver metastases were excluded. Routine MVRs such as 
pancreaticoduodenectomies and splenectomies with pancreatic resections were also 
excluded. We did not exclude any patients based on histopathology. Hospital medical 
records were used to collect complication, hospital stay, recurrence, mortality, and 
histopathology data. Operations were broken down by organs resected. Pre-operative 
status was recorded as per the Charlson Comorbidity Score (CCS) (1). The primary 
outcomes measured were post-operative complications as per the Clavien-Dindo 
Classification (CDC) (Table 1) (2) and Comprehensive Complication Index (CCI) (3).  
Secondary outcomes were recurrence-free survival (RFS) and overall survival (OS). Peri-
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operative death was defined as death within the hospital admission or within 30 days of 
operation. We did not consider medical or radiation oncology in this study. Study data 
were collected and managed using REDCap electronic data capture tools hosted by 
Sydney Local Health District (4).  
Statistical Analysis  
Due to non-normal distribution of CCI, Mann-Whitney U tests were used for comparisons 
between groups. Linear regression was used for comparisons with continuous data. 
Kaplan-Meier analysis was used for RFS and OS with the log-rank test statistic used to 
determine differences in survival distribution. Univariate and multivariate Cox regression 
was used to generate hazard ratios. All statistics were generated using IBM SPSS Version 
24 with p<0.05 considered statistically significant.  
Results 
Patient demographics 
We included 34 patients who underwent surgery from 2012 to September 2016. Patient 
demographics are summarised in Table 2. Nineteen (55.9%) were female, with mean age 
55.6 years (range 16-80). The most common tumour was renal cell carcinoma (RCC, n=6), 
although we combined all soft tissue and osteosarcomas into one group (sarcoma) for 
analysis (n=7). Two patients who had pre-operative imaging suggestive of locally invasive 
malignant tumours had post-operative histopathology where malignancy could not be 
identified (organising haemorrhage and xanthogranulomatous cholecystitis). Nineteen 
(55.9%) patients were pathological stage IV. Nineteen (55.9%) patients had primary 
contiguous tumours, 10 (29.4%) had metastatic cancer (i.e. distant organ or lymph node 
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involvement) either known on presentation or discovered on resection histopathology, and 
5 (14.7%) had recurrence after a primary had been resected. In patients with known 
metastatic disease, the operative goal was resection of all known tumour burden. Median 
(range) Charlson Comorbidity Score (CCS) was 4 (2-7) respectively.  Tumour burden was a 
large contributing factor to the CCS for all patients (76.9% of total scores contributing to 
CCS). 
Operative Details 
Operative factors are summarised in Table 3. Upper gastrointestinal/hepatobiliary 
surgeons were involved in all operations, with other specialist teams being involved when 
appropriate. All biliary reconstructions were performed using a Roux-en-Y technique. 
Operation times ranged from 120 – 785 minutes (median 340 minutes). We used units of 
packed red blood cells (PRBC) as an indicator of blood loss, with a mean and median of 
1.74 and 0 units respectively (range 0-22). Twenty-five (73.5%) patients did not require 
PRBCs. The median (range) ICU and hospital admission was 3 days (1-46) and 13.5 days 
(6-93) respectively. All patients were admitted to ICU immediately post-operatively. If 
patients had more than one ICU admission, their total stay was summed. Organs resected 
by histopathology have been summarised in Table 6. As RCC is the most prevalent 
individual tumour type, we also present individual operations for this diagnosis in Table 7. 
The most frequent organ resected was the liver (n=17, 50%), while the least commonly 
resected anatomy were the aorta and jejunum (both n=1, 2.94%). 
Complications 
A summary of outcomes after surgery, including complications, histopathology and follow 
up are outlined in Table 4. The median (range) highest-CDC grade per patient was II (0-
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IVb), with median (range) CCI of 20.9 (0-78). The median (range) number of complications 
was 2 (0-8). The most common complication was hypotension requiring noradrenaline 
infusion (n=9). The highest-grade complications seen were septic shock and hypotension 
associated with multiorgan failure requiring ICU re-admission (n=1 each). Seven patients 
(20.6%) had no complications recorded. Factors associated with complication outcomes 
are summarised in Table 5. On linear regression, length of ICU admission and length of 
hospital admission had statistically significant correlations with the highest CDC grade 
(p=0.001, p<0.001 respectively). The same result was seen for CCI. On Mann-Whitney U 
test, inferior vena cava (IVC) resection had a statistically significant impact on both CDC 
and CCI (p=0.005, 0.01 respectively). In addition, biliary reconstruction, ileal resection and 
adrenal resection had statistically significant impacts on CCI (p=0.047, 0.043 and 0.027 
respectively). As expected given the definition of complications in Table 1, ICU re-
admission and theatre takeback both had a statistically significant association with CDC 
and CCI. Patient characteristics such as ASA, CCS, age and sex had no statistically 
significant impact on CDC or CCI. 
Recurrence 
Overall recurrence-free survival (RFS) by Kaplan-Meier analysis is demonstrated in Figure 
1. Median RFS was 21 months (95% CI 16.445-25.555). 1 and 3-year RFS was 73% and 
39% respectively. On Kaplan-Meier analysis, liver resection, duodenal resection, and 
presence of lymphatic invasion on histopathology were associated with statistically 
significant decreases in RFS (p<0.001, 0.025, 0.016 respectively), as shown in Figures 2-4. 
Stage, clear resection margins and vascular invasion on histopathology did not impact 
RFS (p=0.497, 0.762 and 0.417 respectively). As seen in Table 8, on univariate Cox 
regression, the same factors as above had statistically significant hazard ratios (HR) 
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impacting RFS (liver resection HR 11.234 [95% CI 2.392-52.759, p=0.002]; duodenal 
resection HR 3.165 [95% CI 1.081-9.267, p=0.036]; lymphatic invasion HR 4.442 [95% CI 
1.157-17.056, p=0.03]). Table 9 shows multivariate analyses of patient characteristics, 
operative characteristics and histopathology on RFS and OS. Liver and retroperitoneal 
resection had statistically significant HRs over other operative details (p=0.006, 0.036 
respectively) for RFS. Metastatic disease had a significant HR when compared to other 
patient characteristics (p=0.039). 
Survival 
Overall survival (OS) is demonstrated in Figure 5. Mean OS was 49.0 months (95% CI 
40.8-57.1). 1 and 3-year OS were both 89.0%. Mean survival of patients with metastatic 
disease was 37.9 months (95% CI 21.58 - 54.24) with actual 5y OS of 37.5%. On Kaplan-
Meier analysis only the presence of metastatic disease significantly impacted OS (p=0.047, 
Figure 6). As per Table 8, on univariate Cox regression only operation time had a 
statistically significant HR of 1.01 (95% CI 1.00-1.02, p=0.021). Table 9 shows multivariate 
analyses. No variable had a significant hazard ratio. There were no peri-operative deaths. 
All long-term deaths were due to tumour recurrence. 
Discussion 
Our cohort contains a wide variety of histology and operations on patients who were often 
treated at a late stage in their disease. In general, these patients have a poor prognosis 
[Table 10, (5-8)] and extensive resection is their only chance of extending survival. The 
undertaking of large resections must be weighed against the risks of post-operative 
complications and impact on quality of life (QOL).  
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Balogh et al. (9) published an early series of 196 patients who underwent extended 
abdominal operations from 1981-1989. The operative mortality rate of patients who had 3 
or more organs resected was 16% and the 5-year overall survival (OS) in patients with 
gastric, pancreatic or rectal cancer with invasion into adjacent organs confirmed on 
histology was 0%. In more recent years, several papers have analysed both morbidity and 
mortality for varying malignancies. For example, Tran et al. (10) (n=159) showed that for 
gastric adenocarcinoma, MVR with pancreatectomy was an independent predictor of poor 
5-year survival and increased post-operative morbidity measured using CDC compared to 
MVR without pancreatectomy, with no significant increase in 30- and 90-day mortality. 
Saito et al. (11) (n=156) demonstrated the importance of R0 resection in gastric 
adenocarcinoma by showing that in patients without liver or peritoneal metastases, MVR 
with complete resection led to a significantly improved survival over patients who did not 
undergo MVR or those that underwent MVR but had lymph node metastases beyond the 
regional nodes. This result held irrespective of the number of organs resected. Within the 
cohort that had complete resection without peritoneal or liver metastases, patients that 
had neither localised tumour and no lymph node spread nor metastatic nodal spread had 
a significantly improved survival over those with infiltrating tumour and metastatic nodal 
spread. Hartwig et al. (12) (n=101) showed that MVR for pancreatic malignancy was 
associated with a significantly higher morbidity compared to standard pancreatectomy, 
although they employed a custom list of complications. There was comparable overall 
survival. McKay et al. (13) used CDC to analyse multivisceral resections in hepatic and 
pancreatic surgery (n=27) and showed a post-operative complication rate of 59% with a 
7% peri-operative mortality. Overall complications including mortality were higher in the 
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pancreatic resection group compared to the hepatic resection group (80% vs 50%, no p 
value supplied). In a series of 249 patient with retroperitoneal sarcomas, Bonvalot et al. 
(14) demonstrated that resection of greater than 3 organs was associated with greater 
morbidity using the Common Terminology Criteria for Adverse Events (15), with the type of 
organ not affecting morbidity. There were 8 (3%) peri-operative deaths and a 5-year OS of 
65%. 
Post-operative complications as per CDC and CCI were highly variable in our cohort, 
ranging from none recorded to re-admission to ICU for multi-organ failure and sepsis. 
Greater morbidity was significantly associated with operation time, adrenal, ileal and IVC 
resection, and biliary reconstruction. Notably, no patient characteristics were significantly 
associated with complication rate including CCS and age. These results can assist in 
surgical planning, consenting and alert hospital staff to patients who will be at higher risk 
of complications during their admission. In the papers discussed above, several used 
custom complication criteria. We believe the use of previously validated complication 
indexes is important to compare patient cohorts and future publications in order to guide 
decision making in the future.  
CCS is a validated index for predicting the risk of death from comorbid disease and has 
been shown to assist in predicting post-operative mortality (16). In our cohort, CCS was 
not significantly associated with CCI, CDC or survival. CCS was largely made up of tumour 
burden, suggesting that carefully selected patients with few additional medical 
comorbidities are suitable for consideration of these operations, and in these selected 
cohorts good peri-operative outcomes are possible. Furthermore, when required, other 
specialist teams were available to assist in resection and all patients were admitted to ICU 
post-operatively. 
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There were no peri-operative deaths and all mortality was due to tumour recurrence 
outside the peri-operative window. It is interesting that the only variable significantly 
impacting OS in our cohort was the presence of metastatic disease, suggesting that 
aggressive surgical therapy has the greatest benefit in patients with large tumour burden 
with local infiltration only. More caution should be taken with those with metastatic 
disease, however our cohort’s 5-year OS with metastatic disease of 37.5% is greater than 
the historical cohort data shown in Table 10. This suggests that even with metastatic 
disease patients should be offered an operation if the goal of that operation is resection of 
all known disease.  
This paper has several limitations. We did not take into consideration the role of 
neoadjuvant or adjuvant therapies such as chemotherapy and radiotherapy. As a 
retrospective cohort analysis, it is subject to confounding factors that were not collected, 
and relies on the accurate documentation of complications in the post-operative period. 
Comparisons to a matched cohort who did not undergo MVR would be beneficial when 
assessing long-term survival. A potential for future studies is to consider the quality of life 
after MVR, which is not considered here and rarely so in the existing literature. 
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Conclusions 
In appropriately selected patients, en-bloc multivisceral resection of upper abdominal 
tumours is safe in centres with specialist surgical teams, anaesthetics and intensivists. 
Complications were not statistically associated with patient factors, however, were 
associated with adrenal, ileal and IVC resection and biliary reconstruction. Short-term 
recurrence-free and overall survival are acceptable given a universally poor outcome for 
the locally invasive or metastatic tumours considered in this cohort. 
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Figures 
Figure 10 Overall recurrence-free survival 
 
  
  
108 
108 
 
Figure 11 Recurrence-free survival curve grouped by presence of lymphatic invasion on histopathology 
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Figure 12 Recurrence-free survival grouped by liver resection as part of MVR 
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Figure 13 Recurrence-free survival grouped by duodenal resection as part of MVR 
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Figure 14 Overall Survival 
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Figure 15 Overall survival grouped by presence of metastatic disease 
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Tables 
Table 1 -  Classification of surgical complications 
Grades Definition 
Grade I Any deviation from the normal postoperative course without the need for pharmacological 
treatment or surgical, endoscopic and radiological interventions  
Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and 
electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. 
Grade II Requiring pharmacological treatment with drugs other than such allowed for grade I 
complications.  
Blood transfusions and total parenteral nutrition are also included. 
Grade III Requiring surgical, endoscopic or radiological intervention 
       - IIIa Intervention not under general anaesthesia 
       - IIIb Intervention under general anaesthesia 
Grade IV Life-threatening complication (including CNS complications) requiring ICU management 
       - IVa single organ dysfunction (including dialysis) 
       - IVb Multiorgan dysfunction 
Grade V Death of a patient 
Suffix "d" If the patient suffers from a complication at the time of discharge, the suffix ‘d’ (for 'disability') is 
added to the respective grade of complication. This label indicates the need for a follow-up to 
fully evaluate the complication. 
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Table 2 - Patient demographics and tumour characteristics 
Age median (range) 56.50 (16-80) 
Female n (%) 19 (55.9) 
CCS median (range) 4.0 (2-7) 
Histopathology n (%) 
Sarcoma 7 (20.59) 
RCC 6 (17.65) 
CRC 5 (14.71) 
Cholangiocarcinoma 3 (8.82) 
Adrenal cortical carcinoma 2 (5.88) 
GIST 2 (5.88) 
Benign 2 (5.88) 
Paraganglioma 2 (5.88) 
Haemangiosarcoma/RCC 1 (2.94) 
Melanoma 1 (2.94) 
Gastric adenocarcinoma 1 (2.94) 
Gallbladder adenocarcinoma 1 (2.94) 
Adenocarcinoma, unknown primary 1 (2.94) 
Tumour load n (%) 
Contiguous 19 (55.9) 
Non-contiguous, metastatic 10 (29.4) 
Non-contiguous, recurrence 5 (14.7) 
Stage n (%) 
Benign 2 (5.9) 
Recurrence 5 (14.7) 
Regional (paraganglioma) 1 (2.9) 
Grade 2 1 (2.9) 
Grade 3 6 (17.6) 
Grade 4 19 (55.9) 
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Table 3 - Operative details 
Operation Time median (range) minutes 340 (120-785) 
PRBC mean (range) units 1.74 (0-22) 
Length of ICU admission median (range) days 3 (1-46) 
Length of Hospital admission median (range) days 13.50 (6-93) 
Intraoperative complications n (%) 4 (11.8) 
 Pleural entry x 2, 
IVC tear, staple 
line failure 
Surgical Specialties n (%)  
Upper gastrointestinal 34 (100) 
Urology 7 (20.59) 
Colorectal 6 (17.65 
Vascular 2 (5.88) 
Cardiothoracics 1 (2.94) 
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Table 4 - Intra- and Post-operative factors 
Complications summary Median (range) 
CCI 20.90 (0-78) 
Highest CDC Grade II (0-IVb) 
Total number of complications 2 (0-8) 
Histopathology  n (%) 
Clear resection margins 26 (76.5) 
Lymphatic invasion 6 (17.6) 
Vascular invasion 10 (29.4) 
Perineural invasion 3 (8.8) 
Post-operative summary  
Follow up (median, range) months 14.71 (2.43-58.13) 
Recurrence-free survival (median, 95% CI) 
months 
21 (16.45-25.56) 
Overall survival (median, 95% CI) months 49.0 (40.78-57.11) 
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Table 5 - Patient and operative factors affecting complications 
Factor Highest CDC grade 
(p) 
CCI 
(p) 
Age 0.22 0.52 
Length of ICU admission 0.001 0.001 
Length of Admission <0.001 <0.001 
ASA 0.97 0.85 
CCS 0.51 0.72 
Operation Time 0.10 0.59 
PRBC 0.15 0.09 
Sex 0.58 0.97 
Metastatic disease 0.40 0.64 
ICU Readmission 0.01 0.004 
Intra-operative Complication 0.15 0.18 
OT Takeback 0.032 0.014 
Liver 0.63 0.15 
Pancreas 0.34 0.36 
Stomach 0.22 0.15 
Ileum 0.37 0.043 
Diaphragm 0.32 0.20 
Colon 0.23 0.068 
Duodenum 0.897 0.67 
Jejunum 1 0.60 
Adrenal 0.14 0.027 
Spleen 0.15 0.41 
Aorta 0.71 0.82 
IVC 0.005 0.01 
Biliary 0.19 0.047 
Kidney 0.18 0.079 
Retroperitoneum 0.71 0.96 
Number organs resected 0.68 0.25 
 
  
118 
118 
Table 6 - Resected organs by histopathology 
Histopathology (n) 
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1 
 
Cholangiocarcinoma (3) 3 2 2 1 2 
      
1 
 
1 
 
Adrenal cortical carcinoma (2) 2 
        
2 2 2 
  
1 
GIST (2) 
 
2 1 2 1 
 
1 1 1 1 1 
    
Benign (2) 1 1 1 
   
1 2 
 
1 
    
1 
Paraganglioma (2) 
         
1 2 2 
  
2 
Haemangiosarcoma/RCC (1) 
         
1 
 
1 
 
1 1 
Melanoma (1) 1 1 1 1 1 
 
1 1 1 
      
Gastric adenocarcinoma (1) 
 
1 
 
1 
    
1 
 
1 
    
Gallbladder adenocarcinoma (1) 1 
  
1 1 
          
Adenocarcinoma, unknown primary (1) 
 
1 
  
1 1 
 
1 
       
  
119 
119 
Table 7 - Individual operation breakdown for RCC resections 
 Organ 
Operation  Liver  Duodenum Kidney Adrenal IVC Aorta Retroperitoneum 
1 1 0 1 1 1 0 1 
2 1 0 1 1 1 0 0 
3 0 1 1 1 1 0 0 
4 0 0 0 0 1 1 1 
5 0 0 1 0 1 0 0 
6 0 0 1 1 1 0 0 
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Table 8 - Factors affecting survival on univariate Cox regression 
 Recurrence-Free Survival Overall Survival 
Factor p HR 95% CI for HR p HR 95% CI for HR 
   Lower Upper   Lower Upper 
Age 0.35 1.02 0.98 1.06 0.43 0.98 0.91 1.04 
Sex 0.31 0.55 0.17 1.77 0.38 0.36 0.037 3.53 
CCS 0.78 0.96 0.71 1.28 0.16 1.58 0.83 3.02 
CCI 0.24 1.01 0.99 1.04 0.94 1.00 0.96 1.05 
Metastatic 0.12 2.32 0.80 6.73 0.088 7.24 0.74 70.51 
PRBCs 0.19 1.07 0.96 1.20 0.087 1.14 0.98 1.33 
Operation Time 0.15 1.00 1.00 1.007 0.021 1.01 1.001 1.02 
Number of Organs Resected 0.42 1.15 0.82 1.62 0.89 0.95 0.44 2.025 
Liver 0.002 11.23 2.39 52.76 0.23 4.07 0.42 39.42 
Pancreas 0.90 1.07 0.36 3.23 0.80 1.31 0.16 11.12 
Biliary Reconstruction 0.16 2.23 0.73 6.74 0.93 0.91 0.091 9.04 
Stomach 0.33 1.74 0.58 5.23 0.45 2.21 0.28 17.39 
Duodenum 0.036 3.17 1.08 9.27 0.43 2.21 0.31 16.02 
Jejunum 0.90 0.88 0.11 6.78 0.67 0.04 0.00 104350 
Ileum 0.99 1.01 0.28 3.66 0.50 0.033 0.00 701.11 
Colon 0.22 0.45 0.13 1.61 0.46 0.42 0.042 4.21 
Spleen 0.32 0.36 0.05 2.75 0.73 1.52 0.14 16.86 
Kidney 0.91 0.94 0.33 2.70 0.83 0.81 0.11 5.80 
Adrenal 0.60 0.73 0.23 2.35 0.68 0.62 0.064 6.00 
IVC 0.44 0.65 0.22 1.92 0.48 0.43 0.043 4.39 
Aorta 0.52 0.044 0.00 669.39 0.82 0.047 0.00 1.06E+10 
Diaphragm 0.75 0.78 0.18 3.51 0.55 0.036 0.00 2041 
Retroperitoneum 0.40 0.61 0.19 1.95 0.46 2.12 0.29 15.546 
Intra-operative Complication 0.34 1.86 0.52 6.67 0.60 0.038 0.00 7905 
Length of ICU 0.72 0.98 0.9 1.08 0.94 1.004 0.89 1.13 
Length of Stay 0.92 1.00 0.97 1.03 0.80 1.007 0.95 1.06 
Clear margins 0.77 1.22 0.34 4.37 0.19 0.27 0.038 1.91 
Vascular invasion 0.43 0.60 0.17 2.1 0.75 0.69 0.071 6.66 
Lympatic invasion 0.03 4.44 1.16 17.06 0.63 1.76 0.18 17.29 
Perineural invasion 0.15 3.35 0.65 17.36 0.75 0.042 0.00 16811310 
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Table 9 - Factors affecting survival on multivariate Cox regression 
 
p HR 95% CI for HR p HR 95% CI for HR    
Lower Upper   Lower Upper 
Patient characteristics  
Sex 0.70 1.33 0.31 5.77 0.73 0.65 0.057 7.43 
age 0.40 1.016 0.98 1.05 0.80 1.00 0.91 1.07 
Metastatic disease 0.048 4.61 1.02 20.92 0.22 6.66 0.32 137.31 
asa 0.068 5.78 0.88 37.75 0.14 10.31 0.46 230.36 
CCS 0.5 0.87 0.57 1.31 0.47 1.44 0.54 3.83 
Operative Factors  
Liver 0.006 4746 11.42 1972781 1.00 0.81 0.00 6.81E+69 
Pancreas 0.87 509.20 0.00 6.00+34 1.00 0.73 0.00 2.89E+102 
Biliary Reconstruction 0.89 0.005 0.00 6.80E+29 0.98 0.046 0.00 6.11E+110 
Stomach 0.93 0.80 4.00E-03 158.53 0.94 0.008 0.00 1.09E+57 
Duodenum 0.081 153.64 0.54 44160 0.97 20.37 0.00 2.50E+64 
Jejunum 0.27 0.011 0.00 33.56 0.93 0.004 0.00 1.55E+53 
Ileum 0.91 42652570 0.00 2.17E+145 1.00 0.38 0.00 2.73E+136 
Colon 0.90 0 0.00 3.04E+129 0.97 0.004 0.00 1.61E+127 
Spleen 0.93 0.79 0.003 180.44 1.00 1.088 0.00 4.70E+78 
Kidney 0.16 117.14 0.16 87932 0.94 0.018 0.00 4.78E+44 
Adrenal 0.89 0.71 5.00E-03 106.70 0.98 12.38 0.00 2.20E+94 
IVC 0.28 0.065 0.00 8.86 0.96 0.001 0.00 6.57E+103 
Aorta 0.98 0.001 0.00 2.14E+287 1.00 1.18 0.00 1.45E+215 
Diaphragm 0.40 6.45 0.08 498.80 0.97 0.041 0.00 1.17E+72 
Retroperitoneum 0.046 51.87 1.08 2487 0.98 4.95 0.00 1.07E+58 
PRBC 0.50 1.127 0.8 1.59 0.98 1.57 0.00 1.08E+13 
Operation Time 0.28 1.00 0.99 1.00 0.93 1.03 0.55 1.93 
Intra-operative Complication 0.90 0.77 0.02 37.90 0.95 0 0.00 2.53E+165 
Histopathology     
Clear Margins 0.78 0.8 0.17 3.74 0.15 0.16 0.014 1.91 
Lymphatic Invasion 0.19 3.27 0.56 19.29 0.81 1.37 0.098 19.27 
Vascular Invasion 0.22 0.23 0.022 2.41 0.50 0.35 0.017 7.10 
Perineural Invasion 0.37 4.25 0.18 98.72 1.00 0 0.00 . 
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Table 10 - A selection of survival statistics for high grade malignancies 
Histology Stage Survival metric % 
RCC Stage IV (Males) 1 year 37.6% 
  5 years 5% 
Colorectal Stage IV (Males) 1 year 43.6% 
  5 years 7% 
Gastric adenocarcinoma Stage IIIC median 11.8 months 
  5 years 11% 
Melanoma Stage IV (Males) 1 47.2% 
  5 8.4% 
Gallbladder adenocarcinoma Stage IV  
Median 
(months) 
5.8 months 
Soft tissue sarcoma Stage III - primary 5 years 48% 
 Stage III - recurrence 5 years 19% 
 
 
 
